Elevai Labs, Inc. Common Stock (ELAB) 10-Q13 Nov 242024 Q3 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2024	Nov. 13, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Entity Information [Line Items]
Entity Registrant Name	ELEVAI LABS INC.
Entity Central Index Key	0001840563
Entity File Number	001-41875
Entity Tax Identification Number	85-1399981
Entity Incorporation, State or Country Code	DE
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	No
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	Graydon Bensler
Entity Address, Address Line Two	120 Newport Center Drive
Entity Address, Address Line Three	Suite 250
Entity Address, City or Town	Newport Beach
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92660
Entity Phone Fax Numbers [Line Items]
City Area Code	(866)
Local Phone Number	794-4940
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	ELAB
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		517,661,269

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current Assets
Cash	$ 6,425,670	$ 3,326,851
Receivables, net	27,887	36,161
Prepaids and deposits	787,848	1,060,765
Inventory, net	986,421	495,667
Total Current Assets	8,227,826	4,919,444
Deposit		10,773
Property and equipment, net	52,528	53,119
Intangibles, net	2,823,530
Operating lease right-of-use asset	101,471	206,582
TOTAL ASSETS	11,205,355	5,189,918
Current Liabilities
Accounts payable and accrued liabilities	1,216,191	669,375
Customer deposits	39,583	36,693
Current portion of consideration payable	350,000
Current portion of lease liability	103,309	145,000
Derivative liabilities	1,882	369,158
Total Current Liabilities	2,130,422	1,297,353
Consideration payable	519,711
Operating lease liability		65,489
TOTAL LIABILIITES	2,650,133	1,362,842
Commitments and Contingencies
EQUITY
Common stock, $0.0001 par value, 300,000,000 shares authorized; 49,376,039 and 17,329,615 shares issued and outstanding as of September 30, 2024, and December 31, 2023, respectively	4,938	1,733
Additional paid-in capital	19,884,944	10,849,031
Accumulated other comprehensive income	228	202
Accumulated deficit	(11,334,888)	(7,023,890)
TOTAL EQUITY	8,555,222	3,827,076
TOTAL LIABILITIES AND EQUITY	11,205,355	5,189,918
Related Party
Current Liabilities
Due to related parties	$ 419,457	$ 77,127

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	49,376,039	17,329,615
Common stock, shares outstanding	49,376,039	17,329,615

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Revenue	$ 527,478	$ 554,654	$ 1,747,570	$ 1,014,004
Cost of sales	133,577	188,509	468,763	341,122
Gross profit	393,901	366,145	1,278,807	672,882
Expenses
Depreciation and amortization	2,686	2,439	7,779	7,824
Marketing and promotion	94,514	99,709	1,209,041	316,436
Consulting fees	235,461	82,781	817,030	316,468
Office and administrative	553,808	664,922	2,096,372	1,628,931
Professional fees	249,889	143,654	587,954	450,384
Investor relations	36,862	9,100	141,484	84,820
Research and development	95,260	86,374	268,786	303,769
Foreign exchange (gain) loss	875	(3,113)	1,660	(480)
Travel and entertainment	44,383	65,830	160,612	250,000
Total Expenses	1,313,738	1,151,696	5,290,718	3,358,152
Net loss before other income (expense)	(919,837)	(785,551)	(4,011,911)	(2,685,270)
Other income (expense)
Change in fair value of derivative liabilities	65,474	8,192	367,277	(451,054)
Interest expense	(648,332)	(5,713)	(702,675)	(12,758)
Interest income	95	25	245	5,481
Other income	1,343		36,066
Net loss	(1,501,257)	(783,047)	(4,310,998)	(3,143,601)
Other comprehensive income (loss)
Currency translation adjustment	(1,014)	387	26	762
Total comprehensive loss	$ (1,502,271)	$ (782,660)	$ (4,310,972)	$ (3,142,839)
Basic loss per share (in Dollars per share)	$ (0.068)	$ (0.078)	$ (0.226)	$ (0.318)
Diluted loss per share (in Dollars per share)	$ (0.068)	$ (0.078)	$ (0.226)	$ (0.318)
Weighted average shares outstanding (in Shares)	22,159,118	10,023,002	19,105,176	9,900,744

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)	Preferred Stock Series Seed 1	Preferred Stock Series Seed 2	Preferred Stock Series A	Common Stock	Additional paid-in capital	Accumulated deficit	Accumulated other comprehensive income	Total
Balance at Dec. 31, 2022	$ 21	$ 364	$ 186	$ 957	$ 3,852,044	$ (2,722,373)	$ 111	$ 1,131,310
Balance (in Shares) at Dec. 31, 2022	213,730	3,635,252	1,861,799	9,568,475
Private placement				$ 49	1,463,537			1,463,586
Private placement (in Shares)				487,859
Share-based compensation					346,548			346,548
Net loss for the period						(3,143,601)		(3,143,601)
Currency translation adjustment							762	762
Balance at Sep. 30, 2023	$ 21	$ 364	$ 186	$ 1,012	5,699,623	(5,865,974)	873	(163,895)
Balance (in Shares) at Sep. 30, 2023	213,730	3,635,252	1,861,799	10,118,834
Exercise of stock options				$ 6	37,494			37,500
Exercise of stock options (in Shares)				62,500
Balance at Jun. 30, 2023	$ 21	$ 364	$ 186	$ 999	5,148,159	(5,082,927)	486	67,288
Balance (in Shares) at Jun. 30, 2023	213,730	3,635,252	1,861,799	9,988,836
Private placement				$ 13	389,984			389,997
Private placement (in Shares)				129,998
Share-based compensation					161,480			161,480
Net loss for the period						(783,047)		(783,047)
Currency translation adjustment							387	387
Balance at Sep. 30, 2023	$ 21	$ 364	$ 186	$ 1,012	5,699,623	(5,865,974)	873	(163,895)
Balance (in Shares) at Sep. 30, 2023	213,730	3,635,252	1,861,799	10,118,834
Balance at Dec. 31, 2023				$ 1,733	10,849,031	(7,023,890)	202	$ 3,827,076
Balance (in Shares) at Dec. 31, 2023				17,329,615				17,329,615
Issued and issuable for acquisition of intangible assets				$ 218	1,610,560			$ 1,610,778
Issued and issuable for acquisition of intangible assets (in Shares)				2,175,000
Issued pursuant to public offering				$ 2,857	7,042,143			$ 7,045,000
Issued pursuant to public offering (in Shares)				28,571,425				950,000
Issued pursuant to Securities Purchase Agreement				$ 130	325,689			$ 325,819
Issued pursuant to Securities Purchase Agreement (in Shares)				1,299,999
Share-based compensation					57,521			57,521
Net loss for the period						(4,310,998)		(4,310,998)
Currency translation adjustment							26	26
Balance at Sep. 30, 2024				$ 4,938	19,884,944	(11,334,888)	228	$ 8,555,222
Balance (in Shares) at Sep. 30, 2024				49,376,039				49,376,039
Balance at Jun. 30, 2024				$ 1,889	12,470,136	(9,833,631)	1,242	$ 2,639,636
Balance (in Shares) at Jun. 30, 2024				18,892,115
Issued and issuable for acquisition of intangible assets				$ 62	(62)
Issued and issuable for acquisition of intangible assets (in Shares)				612,500
Issued pursuant to public offering				$ 2,857	7,042,143			7,045,000
Issued pursuant to public offering (in Shares)				28,571,425
Issued pursuant to Securities Purchase Agreement				$ 130	325,689			325,819
Issued pursuant to Securities Purchase Agreement (in Shares)				1,299,999
Share-based compensation					47,038			47,038
Net loss for the period						(1,501,257)		(1,501,257)
Currency translation adjustment							(1,014)	(1,014)
Balance at Sep. 30, 2024				$ 4,938	$ 19,884,944	$ (11,334,888)	$ 228	$ 8,555,222
Balance (in Shares) at Sep. 30, 2024				49,376,039				49,376,039

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Operating activities
Net loss	$ (4,310,998)	$ (3,143,601)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	9,715	8,737
Share-based compensation	57,521	346,548
Straight-line rent expense	(2,069)	(2,068)
Change in fair value of derivative liabilities	(367,277)	451,054
Non-cash interest expense on notes payable and consideration payable	671,578
R&D costs for intangible assets	61,019
Changes in operating assets and liabilities:
Receivables	8,266	4,507
Prepaid expenses and deposits	283,722	(138,636)
Inventory	(490,754)	(269,164)
Accounts payable and accrued liabilities	383,119	449,281
Customer deposits	2,890	44,681
Due to related parties	206,833	80,000
Cash flows used in operating activities	(3,486,435)	(2,168,661)
Investing activities
Purchase of equipment	(9,160)	(11,191)
Purchase of intangible assets	(162,320)
Cash flows used in investing activities	(171,480)	(11,191)
Financing activities
Net proceeds from issuance of common stock and warrants	6,993,059	1,463,586
Net proceeds from issuance of Notes	914,442
Repayment of Notes	(1,150,000)
Exercise of stock options		37,500
Cash flows provided by financing activities	6,757,501	1,501,086
Effect of exchange rate changes on cash	(767)	720
Increase (decrease) in cash	3,098,819	(678,046)
Cash, beginning of period	3,326,851	1,154,901
Cash, ending of period	6,425,670	476,855
Supplemental cash flow information:
Cash paid for interest	23,248	4,898
Cash paid for taxes
Non-cash Investing and Financing transactions:
Common stock issued and issuable on acquisition of intangible asset	$ 1,610,778

Organization and Nature of Oper

Organization and Nature of Operations	9 Months Ended
Organization and Nature of Operations	Sep. 30, 2024
Organization and Nature of Operations [Abstract]
Organization and nature of operations	1. Organization and nature of operations Elevai Labs Inc. (“Elevai”) was incorporated under the laws of the State of Delaware on June 9, 2020. Elevai and its 100% owned subsidiaries, Elevai Research Inc., Elevai Skincare Inc., and Elevai Biosciences, Inc., are collectively referred to in these unaudited condensed consolidated financial statements as “the Company.” The Company is a skincare development company engaged in the design, manufacture, and marketing of skincare products in the skincare industry. The Company’s principal activities are developing and manufacturing skincare products. On April 29, 2024, Elevai Skincare Inc. ("Skincare”) and Elevai Biosciences, Inc. (“BioSciences”) were incorporated under the laws of the state of Delaware. Elevai is the sole shareholder of Skincare and BioSciences. The purpose of Skincare is to operate the Company’s existing business, while the purpose of BioSciences is to hold and develop the Company’s intellectual property. Effective May 1, 2024, Elevai transferred its operating assets and liabilities relating to its skincare business to Skincare in exchange for common stock of Skincare.

Going Concern

Going Concern	9 Months Ended
Going Concern	Sep. 30, 2024
Going Concern [Abstract]
Going Concern	2. Going Concern These unaudited condensed consolidated financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the continued financial support from its shareholders and the ability of the Company to obtain necessary equity financing to continue operations, and ultimately the attainment of profitable operations. As of September 30, 2024, and December 31, 2023, the Company had a net working capital of $6,097,404 and $3,622,091, respectively, and has an accumulated deficit of $11,334,888 and $7,023,890, respectively. Furthermore, for the nine months ended September 30, 2024, and 2023, the Company incurred a net loss of $4,310,998 and $3,143,601, respectively, and used $3,486,435 and $2,168,661, respectively of cash flows for operating activities. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These unaudited condensed consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The assessment of whether the going concern assumption is appropriate requires management to take into account all available information about the future, which is at least, but not limited to, 12 months from the date the financial statements are issued. The Company is aware that material uncertainties related to events or conditions may cast substantial doubt upon the Company’s ability to continue as a going concern. Management’s plans that alleviate substantial doubt about the Company’s ability to continue as a going concern include raising additional debt or equity financing. Although the Company has been successful in raising funds in the past, and expects to do so in the future, there are no guarantees that it will be able to raise funds as anticipated.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2024
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies Basis of Presentation These unaudited condensed consolidated financial statements have been prepared in accordance with rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and generally accepted accounting principles in the United States (“U.S. GAAP”) for interim financial information and are expressed in United States dollars. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, we have included all adjustments considered necessary for a fair presentation and such adjustments are of a normal recurring nature. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the years ended December 31, 2023, and 2022. The results of operations for the nine months ended September 30, 2024, are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2024. Principles of Consolidation The unaudited condensed consolidated financial statements include the account of Elevai, and its 100% owned subsidiaries, Elevai Research Inc., Skincare, and BioSciences. All intercompany accounts, transactions and profits were eliminated in the unaudited condensed consolidated financial statements. Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to revenue recognition, the collectability of receivables, valuation of inventory, fair value of derivative liabilities and stock options, useful lives and recoverability of long-lived assets, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying value of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from those estimates. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the unaudited condensed consolidated financial statements in the period they are determined. Foreign Currency Translation The Company’s functional and reporting currency is the U.S. dollar. The functional currency of Elevai Research Inc. is the Canadian dollar. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Non-monetary assets, liabilities, and items recorded in income arising from transactions denominated in foreign currencies are translated at rates of exchange in effect at the date of the transaction. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in the determination of income. The accounts of Elevai Research Inc. are translated to U.S. dollars using the current rate method. Accordingly, assets and liabilities are translated into U.S. dollars at the period-end exchange rate while revenues and expenses are translated at the average exchange rates during the period. Related exchange gains and losses are included in a separate component of stockholders’ equity as accumulated other comprehensive income (loss). Intangible Assets In accordance with ASC 350 “Intangibles—Goodwill and Other”, intangible assets are recorded at cost less accumulated amortization. They are depreciated using the straight-line method over their estimated useful lives, which reflect the period over which economic benefits are expected to be realized. In accordance with ASC 730 “Research and development costs”, an acquired in-process researched and development (“IPR&D”) intangible asset with an alternative future use is capitalized, in accordance with ASC 350, and amortized over its useful life. Although IPR&D assets are likely to be finite-lived, amortization does not begin until the research and development projects are completed. In accordance with the IPR&D asset purchase agreement, the Company is required to meet development milestones starting with the initiation of a pre-clinical IND-enabling study within 2 years of the acquisition date, and ending with obtaining marketing approval from the FDA within 9 years of the acquisition date. Management assesses impairment indicators at each reporting period end. The estimated useful lives of intangible assets are generally as follows: License #1 10-year straight-line License #2 IPR&D project not yet complete Accounting for Freestanding Instruments Issued Together The Company accounts for multiple instruments issued together in accordance with ASC 470 “Debt”, ASC 480 “Distinguishing Liabilities from Equity” and ASC 505 “Equity”. The Company first identifies all freestanding instruments. When multiple freestanding instruments are issued in a single transaction, the total proceeds from the transaction are allocated among the individual freestanding instruments identified based on their relative fair values at issuance. Transaction costs that are directly attributable to the issuance of both debt and equity are allocated between the liability and equity components based on their relative fair values. New Accounting Standards Recently Adopted Accounting Standards In March 2022, the FASB issued ASU 2022-02, ASC Subtopic 326 “Credit Losses”: Troubled Debt Restructurings and Vintage Disclosures. Since the issuance of Accounting Standards Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, the Board has provided resources to monitor and assist stakeholders with the implementation of Topic 326 (“Update”). Post-Implementation Review (PIR) activities have included forming a Credit Losses Transition Resource Group, conducting outreach with stakeholders of all types, developing educational materials and staff question-and-answer guidance, conducting educational workshops, and performing an archival review of financial reports. ASU No. 2022-02 is effective for annual and interim periods beginning after December 15, 2022. The adoption of this standard did not have a significant impact on the Company’s unaudited condensed consolidated financial statements. In June 2022, the FASB issued ASU 2022-03, ASC Subtopic 820 “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”. The FASB is issuing this Update (1) to clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. Stakeholders asserted that the language in the illustrative example resulted in diversity in practice on whether the effects of a contractual restriction that prohibits the sale of an equity security should be considered in measuring that equity security’s fair value. Some stakeholders apply a discount to the price of an equity security subject to a contractual sale restriction, whereas other stakeholders consider the application of a discount to be inappropriate under the principles of Topic 820. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The adoption of this standard did not have a significant impact on the Company’s unaudited condensed consolidated financial statements. Recently Issued Accounting Standards The Company assesses the adoption impacts of recently issued, but not yet effective, accounting standards by the Financial Accounting Standards Board on the Company’s unaudited condensed consolidated financial statements. There are no recently issued accounting standards which may have effect on the Company’s unaudited condensed consolidated financial statements

Receivables

Receivables	9 Months Ended
Receivables	Sep. 30, 2024
Receivables [Abstract]
Receivables	4. Receivables As of September 30, 2024, receivables consisted of the following: September 30, December 31, Trade receivable $ 16,889 $ 33,089 Sales taxes receivable 10,998 3,072 $ 27,887 $ 36,161 The Company records sales taxes receivable for recoverable sales taxes paid on eligible purchases in its Canadian subsidiary. As at September 30, 2024, and December 31, 2023, the Company recorded a provision for credit losses of $ nil nil

Prepaids and Deposits

Prepaids and Deposits	9 Months Ended
Prepaids and Deposits	Sep. 30, 2024
Prepaids and Deposits [Abstract]
Prepaids and Deposits	5. Prepaids and Deposits As of September 30, 2024, and December 31, 2023, prepaid and deposits consisted of the following: September 30, December 31, Prepaid expenses $ 651,984 $ 957,645 Deposits 135,864 113,893 $ 787,848 $ 1,071,538 Prepaids and deposits - current 787,848 1,060,765 Deposits- non-current - 10,773 As of December 31, 2023, the security deposit on the Company’s long-term lease in the amount of $10,773 is classified as a non-current deposit on the balance sheet. As this lease term is expected to end in May 2025, this non-current deposit is classified as current on the balance sheet as at September 30, 2024.

Inventory

Inventory	9 Months Ended
Inventory	Sep. 30, 2024
Inventory [Abstract]
Inventory	6. Inventory As of September 30, 2024, and December 31, 2023, inventory consisted of the following: September 30, December 31, Raw materials $ 439,328 $ 279,514 Work in progress 289,113 147,906 Finished goods 257,980 68,247 $ 986,421 $ 495,667 Cost of inventory recognized as expense in cost of sales for the nine months ended September 30, 2024, and 2023, totaled $214,272 and $193,805, respectively. In addition, the cost of inventory relating to samples given out and expensed in marketing and promotion for the nine months ended September 30, 2024, and 2023, totaled $134,000 and $96,184, respectively. As of September 30, 2024, and December 31, 2023, the Company recorded an allowance for inventory of $ nil nil

Property and Equipment

Property and Equipment	9 Months Ended
Property and Equipment	Sep. 30, 2024
Property and Equipment [Abstract]
Property and equipment	7. Property and Equipment Equipment Furniture Computers Total Cost Balance, December 31, 2022 $ 50,516 $ 8,365 $ 2,759 $ 61,640 Additions 2,658 8,533 - 11,191 Foreign currency translation - - 61 61 Balance, December 31, 2023 $ 53,174 $ 16,898 $ 2,820 $ 72,892 Additions 9,160 - - 9,160 Foreign currency translation - - (54 ) (54 ) Balance, September 30, 2024 $ 62,334 $ 16,898 $ 2,766 $ 81,998 Accumulated depreciation Balance, December 31, 2022 $ 7,052 $ 548 $ 505 $ 8,105 Depreciation 8,680 2,414 555 11,649 Foreign currency translation - - 19 19 Balance, December 31, 2023 $ 15,732 $ 2,962 $ 1,079 $ 19,773 Depreciation 7,492 1,811 412 9,715 Foreign currency translation - - (18 ) (18 ) Balance, September 30, 2024 $ 23,224 $ 4,773 $ 1,473 $ 29,470 Net book value December 31, 2023 $ 37,442 $ 13,936 $ 1,741 $ 53,119 September 30, 2024 $ 39,110 $ 12,125 $ 1,293 $ 52,528 During the nine months ended September 30, 2024, and 2023, the Company capitalized depreciation of $1,936 and $914, respectively as part of the production of inventory.

Intangible Assets

Intangible Assets	9 Months Ended
Intangible Assets	Sep. 30, 2024
Intangible Assets [Abstract]
Intangible assets	8. Intangible assets On January 15, 2024, the Company entered into a license agreement with a biotechnology company to use their proprietary technology and process to assist in formulating stem cells (“License #1”). The term of the license is 10 years and has a purchase price of $1,000,000. The payment structure for License #1 is as follows: a) $50,000 payable upon executing the license (paid); b) $350,000 payable on March 15, 2025 (updated from July 15, 2024 in an amendment dated July 9, 2024); and c) $600,000 payable on completion of technology transfer or two years from January 15, 2024, whichever comes first. The cost of License #1 was measured at $861,452, which is the fair value of the consideration payable on initial recognition, determined by discounting the future payments using a market interest rate of 11.75%. On April 30, 2024, the Company entered into an exclusive license agreement with a pharmaceutical company granting the Company rights to develop, manufacture, and commercialize licensed products (“License #2”). The Company has classified License #2 as an IPR&D asset resulting in only the acquisition costs plus any transaction costs to be capitalized upon acquisition. The research and development project associated with License #2 is not yet complete and as a result the Company has not yet determined the useful life of the IPR&D asset. The Company paid consideration of $400,000 and 950,000 shares of common stock with a value of $492,850 to the pharmaceutical company. The shares issued to the pharmaceutical company are unregistered and subject to trading restrictions for six months from the issue date resulting in a fair value discount adjustment of $173,100 on the value of the common stock issued to the pharmaceutical company. The Company incurred transaction costs of $12,320 in legal fees and $1,117,771 in common stock paid to a consultant who assisted in acquiring License #2. The common stock to be issued to the consultant will be unregistered and subject to trading restrictions for a 1-year period from the issue date of the first tranche resulting in a fair value discount adjustment of $599,863 on the value of the common stock issued to the consultant. The fair value adjustments were calculated using the Black-Scholes Option Pricing Model. The Black-Scholes Option Pricing Model requires six basic data inputs: the exercise or strike price, expected time to expiration or exercise, the risk-free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. Changes to these inputs could produce a significantly higher or lower fair value measurement. The following assumptions were used in the Black-Scholes option pricing model: Initial Risk-free interest rate 5.12-5.44% Expected life 0.5-1 years Expected dividend rate 0.00% Expected volatility 100% The consultant is to receive 2,450,000 shares of common stock in the following tranches and all shares were earned (i.e. fully vested) upon the Company’s acquisition of License #2 as follows: ● May 3, 2024: 612,500 shares (issued) ● August 1, 2024: 612,500 shares (issued) ● November 1, 2024: 612,500 shares (issued – Note 18) ● February 2, 2025: 612,500 shares The cost of License #2 IPR&D asset is $2,023,097, which is the fair value of the consideration paid on initial recognition. License #1 License #2 Total Cost Balance, December 31, 2023 $ - - - Additions 861,452 2,023,097 2,884,549 Balance, September 30, 2024 $ 861,452 2,023,097 2,884,549 Accumulated amortization Balance, December 31, 2023 $ - - - Additions 61,019 - 61,019 Balance, September 30, 2024 $ 61,019 - 61,019 Net Book value – September 30, 2024 $ 800,433 2,023,097 2,823,530

Operating Lease

Operating Lease	9 Months Ended
Operating Lease	Sep. 30, 2024
Operating Lease [Abstract]
Operating Lease	9. Operating Lease During 2022, the Company entered into a non-cancelable operating lease that includes two property locations, one which is being used as the Company’s office and the other as its lab for research and development and the production of inventory. The lease had a commencement date of June 1, 2022, and expires on May 31, 2025, after which the term will continue on a month-to-month basis. On July 3, 2023, the Company amended the terms of the previously entered lease agreement to lease additional office space from the lessor. Rent increased from $10,773 to $13,477 per month commencing July 1, 2023, through May 31, 2025. The lease amendment required a remeasurement of the lease liability which resulted in an increase of $47,986 to the lease liability and an equal increase in the right-of-use asset as of July 1, 2023. The Company used a discount rate of 11.50% upon the remeasurement of the lease liability on July 1, 2023, compared to an original discount rate of 8% on lease commencement, as its incremental cost of borrowing due to the amendment. The Company recognized a total lease cost related to its non-cancelable operating lease of $119,222 and $103,000 for the nine months ended September 30, 2024, and 2023, respectively. The lease cost has been allocated as follows based on the square footage of each property location. September 30, September 30, Office space, recorded in office and administration $ 90,863 $ 74,640 Lab space, recorded in research and development 18,688 23,705 Lab space, capitalized to production of inventory 9,671 4,655 $ 119,222 $ 103,000 As of September 30, 2024, and December 31, 2023, the Company recorded a security deposit of $10,773 (Note 5). Future minimum lease payments under the Company’s operating lease that have an initial non-cancelable lease term in excess of one year at September 30, 2024, are as follows: As of September 30, 2024 Total 2024 40,430 2025 67,384 Thereafter - 107,814 Less: Imputed interest (4,505 ) Operating lease liability 103,309 Operating lease lability – current 103,309 Operating lease lability – non-current $ - The remaining lease term as of September 30, 2024, is 0.67 years (December 31, 2023 – 1.42 years).

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	9 Months Ended
Accounts Payable and Accrued Liabilities	Sep. 30, 2024
Accounts Payable and Accrued Liabilities [Abstract]
Accounts Payable and Accrued Liabilities	10. Accounts Payable and Accrued Liabilities As of September 30, 2024, and December 31, 2023, accounts payable and accrued liabilities consisted of the following: September 30, December 31, Accounts payable $ 1,078,624 $ 596,147 Accrued liabilities 137,567 73,228 $ 1,216,191 $ 669,375

Consideration Payable

Consideration Payable	9 Months Ended
Consideration Payable	Sep. 30, 2024
Consideration Payable [Abstract]
Consideration payable	11. Consideration payable On January 15, 2024, the Company entered into a license agreement with a Biotechnology company to use their proprietary technology and process to assist in formulating stem cells. The remaining amount of the payments to be made in accordance with the interest-free payment schedule disclosed in Note 8 is $950,000. The Company has accounted for a discount, using a market interest rate of 11.75%, on the consideration payable to reflect the imputed interest on future installments, totaling $138,548. Consideration Outstanding, December 31, 2023 $ - Additions 861,452 Payment (50,000 ) Accretion expense 58,259 Outstanding, September 30, 2024 $ 869,711 Consideration payable – current 350,000 Consideration payable – non-current $ 519,711

Derivative Liabilities

Derivative Liabilities	9 Months Ended
Derivative Liabilities	Sep. 30, 2024
Derivative Liabilities [Abstract]
Derivative liabilities	12. Derivative liabilities On July 15, 2022, the Company issued 231,828 common stock purchase warrants with an exercise price of $2.01 as part of the conversion of promissory notes. On November 21, 2023, the Company completed its Initial Public Offering (“IPO”) and issued 75,000 warrants (the “IPO warrants”). Each IPO warrant is exercisable into one share of common stock of the Company at $4 per share and expire on November 21, 2028. We analyzed the common stock purchase warrants issued as partial settlement of the promissory notes payable and the IPO warrants against the requirements of ASC 480, Distinguishing Liabilities from Equity, and determined that the warrants should be classified as financial liabilities. ASC 815, Derivatives and Hedging, requires that the warrants be accounted for as derivative liabilities with initial and subsequent measurement at fair value with changes in fair value recorded as other income (expense). A continuity of the Company’s common stock purchase derivative liability warrants is as follows: Derivative Outstanding, December 31, 2022 $ 68,455 Addition of new derivatives during IPO 229,437 Change in fair value of derivative liabilities 71,266 Outstanding, December 31, 2023 $ 369,158 Change in fair value of derivative liabilities (367,277 ) Outstanding, September 30, 2024 $ 1,881 We determined our derivative liabilities to be a Level 3 fair value measurement and used the Black-Scholes Option Pricing Model to calculate the fair value as of initial recognition and as of September 30, 2024, and December 31, 2023. The Black-Scholes Option Pricing Model requires six basic data inputs: the exercise or strike price, expected time to expiration or exercise, the risk-free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. Changes to these inputs could produce a significantly higher or lower fair value measurement. The following assumptions were used in the Black-Scholes option pricing model: September 30, December 31, November 21, December 31, July 15, Risk-free interest rate 3.58 % 3.84 - 4.01% 4.41 % 4.73 % 3.12 % Expected life 1 2.57 – 4.15 years 3.32 – 4.90 years 5 years 0.75 years 0.6 years Expected dividend rate 0 % 0 % 0.00 % 0.00 % 0.00 % Expected volatility 100 % 100 % 100 % 100 % 100 % As of September 30, 2024, the following derivative liability warrants were outstanding: Outstanding Expiry date 1 Weighted average 75,840 April 27, 2027 2.01 63,037 April 27, 2027 2.01 80,388 April 27, 2027 2.01 12,563 April 27, 2027 2.01 75,000 November 21, 2028 4.00 306,828 2.50 As of September 30, 2024, and December 31, 2023, the weighted average life of derivative liability warrants outstanding was 2.96 and 3.71 years, respectively. 1 On April 28, 2023, the Company amended the warrant agreements for the 231,828 derivative liability warrants outstanding. The amendment removed the clause to automatically convert warrants to shares on IPO date and all warrants were given an expiry date of April 27, 2027. This led to an increase in the expected life input in the Black-Scholes model as of December 31, 2023, compared to December 31, 2022, when the Company used the expected IPO date to calculate the expected life of the warrants.

Notes Payable

Notes Payable	9 Months Ended
Notes Payable	Sep. 30, 2024
Notes Payable [Abstract]
Notes payable	13. Notes payable On July 31, 2024, the Company signed a securities purchase agreement (the “Securities Purchase Agreement”) to sell an aggregate of $1,150,000 in Notes with a $150,000 original issue discount. Pursuant to the Securities Purchase Agreement, the Company also agreed to issue 1,299,999 shares of common stock (Note 14). Given the original issue discount, the subscription amount received by the Company was an aggregate of $1,000,000. The Notes were non-interest bearing except in the event of default, in which case interest would accrue at 14% per annum. The maturity date of the Notes was 90 days from the date of issuance. While the Notes were outstanding, the Company agreed to use the net proceeds of any offering of its equity or debt securities to first redeem the Notes in full, including the principal amount and all other amounts due and payable pursuant to the Notes. The fair value of the Notes was $622,239. The Company incurred total transaction costs of $137,500 in relation to the Security Purchase Agreement, of which $85,558 was attributed to the issuance of the Notes and $51,942 was attributed to the issuance of common stock. The Company repaid $1,150,000 in relation to the Notes Payable in September 2024, resulting in a Notes payable balance of $ nil A continuity of the Company’s Notes Payable during the nine months ended September 30, 2024 is as follows: Notes Outstanding, December 31, 2023 $ - Fair value of Notes issued 622,239 Transaction costs (85,558 ) Interest accretion 613,319 Repayment (1,150,000 ) Outstanding, September 30, 2024 $ -

Equity

Equity	9 Months Ended
Equity	Sep. 30, 2024
Equity [Abstract]
Equity	14. Equity Common Stock Authorized As of September 30, 2024, and December 31, 2023, the Company had 300,000,000 common stock authorized, each having a par value of $0.0001. Issued and outstanding As of September 30, 2024, and December 31, 2023, the Company had 49,376,039 and 17,329,615 shares issued and outstanding, respectively. Transactions during the nine months ended September 30, 2024 On April 30, 2024, the Company issued 950,000 common stock on acquisition of License #2 and $492,945 was recognized in equity. A total of $95 was recognized in common stock and the remainder of $492,850 to additional paid in capital (Note 8). These shares are unregistered and restricted from trading as disclosed in Note 8. On May 3, 2024, the Company committed to issue 2,450,000 fully vested shares for the acquisition of License #2. As at September 30, 2024, 1,225,000 of these shares have been issued. A total of $1,117,833 was recognized in equity in relation to the issuance of these shares, of which $123 was recognized in common stock and the remainder of $1,117,710 to additional paid in capital (Note 8). These shares are unregistered and restricted from trading as disclosed in Note 8. On August 2, 2024, the Company issued 1,299,999 shares as consideration for purchasers who entered into the Securities Purchase Agreement (Note 13). Transaction costs of $51,942 were associated with this share issuance. A total of $325,819 was recognized in equity, of which $130 was recognized in common stock and the remainder of $325,689 to additional paid in capital. On September 24, 2024, the Company issued 8,900,000 shares of the Company’s common stock and 19,671,425 pre-funded warrants in lieu of shares of common stock, along with 51,142,850 common stock purchase warrants. The purchasers had the option to elect to purchase pre-funded warrants in lieu of common shares in order to avoid exceeding the Beneficial Ownership Limitation, which is 4.99% (or 9.99% upon election of the holder prior to the issuance of any warrants) of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock issuable upon exercise of the warrant. The pre-funded warrants had an exercise price of $0.0001, had no expiry date and had a cashless exercise provision. All pre-funded warrants were exercised by September 30, 2024. The purchase price of each share of common stock and accompanying warrants was $0.28, and the purchase price of each pre-funded warrant and accompanying warrants was equal to such price minus $0.0001. Share issuance costs of $955,000 were associated with this offering. A total of $7,045,000 was recognized in equity, of which $2,857 was recognized in common stock and the remainder of $7,042,143 to additional paid in capital. Transactions during the nine months ended September 30, 2023 On January 6, 2023, the Company issued 62,500 common stock upon the exercise of 62,500 stock options with an exercise price of $0.60 per common stock for $37,500, of which $6 was recognized in common stock and the remaining $37,494 in additional paid-in capital. On March 2, 2023, the Company issued 250,000 common stock and 250,000 common stock purchase warrants for $750,000, of which $25 was recognized in common stock and the remaining $749,975 in additional paid-in capital. These warrants are accounted for as equity warrants. On April 14, 2023, the Company issued 97,681 common stock, of which $10 was recognized in common stock and the remaining $293,579 in additional paid-in capital. On May 15, 2023, the Company issued 10,000 common stock, of which $1 was recognized in common stock and the remaining $29,999 was recognized in additional paid-in capital. On August 25, 2023, the Company issued 46,666 common stock, of which $5 was recognized in common stock and the remaining $139,995 was recognized in additional paid-in capital. On September 13, 2023, the Company issued 83,882 common stock and 99,998 common stock purchase warrants, of which $8 was recognized in the common stock and the remaining $249,996 was recognized in additional paid-in capital. These warrants are accounted for as equity warrants. Preferred Stock Authorized As of September 30, 2024, and December 31, 2023, the Company had 75,000,000 of all preferred stock authorized, each having a par value of $0.0001 per stock. The holders of Preferred Stock shall have the right to convert their shares of Preferred Stock, at any time, into shares of Common Stock at a conversion price of 1:1. Upon IPO, all preferred shares were converted into common stock on November 21, 2023. Issued and outstanding As at September 30, 2024, and December 31, 2023, the Company had Nil Transactions during the nine months ended September 30, 2024, and 2023 There were no preferred stock transactions during the nine months ended September 30, 2024, and 2023. Equity Warrants Transactions during the nine months ended September 30, 2024. On September 24, 2024, with each of the 28,571,425 shares of common stock or pre-funded warrants issued on the same date, the Company also issued one Series A Warrant (the “Series A Warrants”) and one Series B Warrant (the “Series B Warrants”). The Series A Warrants will be exercisable beginning on the date of completion of the requisite waiting period following the filing of the Information Statement related to the approval by the stockholders of the Company (the “Initial Exercise Date” or “Shareholder Approval Date”) of the issuance of shares upon exercise of the Warrants, among other things (the “Shareholder Approval”). The Initial Exercise Date was October 30, 2024. The Series B Warrants will be exercisable beginning on the Shareholder Approval Date. The Series A Warrants will expire on the five-year anniversary of the Initial Exercise Date and the Series B Warrants will expire on the two and one-half-year anniversary of the Initial Exercise Date. The exercise price of the Series A and Series B Warrants shall be $0.38, subject to adjustments, including the following: A. On the day that is the eleventh trading day following the Initial Exercise Date (the “Reset Date”), the exercise price shall be adjusted to equal the reset price (the “Reset Price”), which is the greater of: (i) the lowest daily volume-weighted average price (“VWAP”) during the 10-day period following the Initial Exercise Date (the “Reset Period”); and (ii) the floor price in effect as of the Reset Date, being a price equal to $0.056 (the “Floor Price”). B. Upon reset of the Series A and Series B Warrants’ exercise price, the number of Series A and Series B Warrants and the number of common shares issuable shall be increased such that the aggregate exercise price (“Initial Exercise Value”) on the issuance date shall remain unchanged following such reset. Furthermore, holders of the Series B Warrants may effect an “alternative cashless exercise”. In such an event, the aggregate number of common shares issuable in such alternative cashless exercise shall equal the product of (i) the aggregate number of common shares that would be issuable upon exercise of a Series B Warrant if such exercise were by means of a cash exercise rather than a cashless exercise, multiplied by (ii) 3.0. On September 24, 2024, the Company issued 1,428,571 placement agent warrants to the placement agent in connection with the financing that closed on the same date (the “Placement Agent Warrants”). These Placement Agent Warrants have an exercise price of $0.336 and shall expire three and a half years from issuance. As these warrants are accounted for as equity warrants, they have no net impact on the consolidated statement of changes in stockholders’ equity. Transactions during the nine months ended September 30, 2023 On March 2, 2023, the Company issued 250,000 common stock and 250,000 common stock purchase warrants. Each warrant is exercisable at $3.00 per common stock. The warrants are exercisable, in whole or in part at the issue date but such exercisability shall cease upon the date of the Company’s IPO and listing of its common stock on the Nasdaq Capital Market or other Trading Market (as defined below) and shall continue to be exercisable in whole or in part immediately after the Lock-up Period but no later than the Warrant Expiration Date or Accelerated Warrant Expiration Date (the period in which these warrants are exercisable, the “Exercise Period”). In the event of the Company’s initial public offering and listing of shares of its common stock on a Trading Market, the Company shall notify the holder at least fifteen (15) calendar days prior to the consummation of such IPO. “Trading Market” shall mean a "national securities exchange" that has registered with the SEC under Section 6 of the Exchange Act. The Expiration Date shall be the earlier of (i) three years and one hundred eighty (180) days from the issue date (the “Warrant Expiration Date”) or (ii) upon the Company’s reasonable judgment and written notice to the purchaser, of the Company’s option to accelerate the Warrant Expiration Date whereby upon purchaser’s receipt of the Company’s written notice of acceleration during the Exercise Period, the Purchaser’s option to exercise any number of warrants shall occur no later than fourteen (14) days following the receipt of the written notice of acceleration (the “Accelerated Warrant Expiration Date”). For the avoidance of doubt, it shall be reasonable for the Company to accelerate the Expiration Date of this warrant to coincide with transactions including, but not limited to (i) a change of control including but not limited to the voluntary or involuntary sale, assignment, transfer or other disposition, or transfer by operation of law, of more than 50% of any direct or indirect equity interest of the Company; or (ii) a subsequent capital financing other than the IPO consisting of but not limited to an offer or proposal for, or indication of interest in, the issuance of debt or the capital stock of the Company. On September 13, 2023, the Company issued 83,332 common stock and 99,998 common stock purchase warrants. Each warrant is exercisable at $3.00 per common stock. The Warrants shall be exercisable, in whole or in part immediately upon issuance, but such exercisability shall cease upon the date of the Company’s initial public offering (the “IPO”) and listing of its common stock on the Nasdaq Capital Market or other Trading Market (as defined herein) and will only become exercisable after the expiration of one hundred eighty (180) days following the Company’s initial public offering (the “Lock-up Period”). The expiration date shall be three years and one hundred eighty (180) days following the issuance of the Warrant Shares. As of September 30, 2024, the following equity warrants were outstanding: Outstanding Expiry date Weighted average 250,000 August 28, 2026 3.00 99,998 March 12, 2027 3.00 28,571,425 1 October 30, 2029 0.38 1 28,571,425 2 April 30, 2027 0.38 2 1,428,571 March 24, 2028 0.34 58,921,419 0.39 1 As of the Reset Date, the exercise price of the Series A Warrants has been adjusted to the Floor Price of $0.056. In addition, the number of Series A Warrants outstanding was adjusted to 193,877,526 such that the Initial Exercise Value on the issuance date remained unchanged. 2 As of the Reset Date, the exercise price of the Series B Warrants has been adjusted to the Floor Price of $0.056. In addition, the number of Series B Warrants outstanding was adjusted to 188,194,300 such that the Initial Exercise Value on the issuance date remained unchanged. As of September 30, 2024, and December 31, 2023, the weighted average life of equity warrants outstanding was 3.81 and 2.81 years, respectively. Stock Options The Company has a stock option plan included in the Company’s 2020 Equity Incentive Plan (the “Plan”) where the Board of Directors or any of its committees can grant Incentive Stock Options, Nonstatutory Stock Options, and Restricted Stock to employees, advisors and directors of the Company. As of December 31, 2023 and 2022, the aggregate number of shares allocated and made available for issuance pursuant to stock options granted under the Plan shall not exceed 1,734,188 shares. The plan shall remain in effect until it is terminated by the Board of Directors. Transactions during the nine-month ended September 30, 2024 In January 2024, the Company granted 12,500 stock options with a contractual life of ten years and an exercise price of $5.00 per common stock. These stock options were valued at $16,178 using the Black-Scholes Option Pricing Model. The options vest 25% on the first anniversary of the grant date and the remaining 75% vest evenly over 36 months thereafter. On March 6, 2024, the Company granted 80,000 stock options with a contractual life of ten years and an exercise price of $1.00 per common stock. These stock options were valued at $52,845 using the Black-Scholes Option Pricing Model. The options vest 25% on the first anniversary of the grant date and the remaining 75% vest evenly over 36 months thereafter. Transactions during the nine-month ended September 30, 2023 On February 1, 2023, the Company granted 10,000 stock options with a contractual life of ten years and an exercise price of $5.00 per common stock. These stock options were valued at $10,767 using the Black-Scholes Option Pricing Model. The options vest 25% on the first anniversary of the grant date and the remaining 75% vest evenly over 36 months thereafter. From May 12, 2023, to June 30, 2023, the Company granted 222,500 stock options (includes 80,000 each to two of its newly appointed independent directors) with a contractual life of ten years and an exercise price of $5.00 per common stock. These stock options were valued at $584,787 using the Black-Scholes Option Pricing Model. The options vest 25% on the first vesting date and the remaining 75% vest evenly over 36 months thereafter. On June 30, 2023, the Company cancelled and reissued 80,000 options previously issued to an advisor of the Company upon their appointment as a director effective June 1, 2023. The cancelled and re-issued options had the same exercise price of $5.00 per common stock and the same vesting terms and expiry date, and as such the cancellation and reissuance had no impact on the Company’s consolidated financial statements. On July 1, 2023, the Company granted 1,500 stock options with a contractual life of ten years and an exercise price of $5.00 per common stock. These stock options were valued at $3,940 using the Black-Scholes Option Pricing Model. The options vest 25% on the first vesting date and the remaining 75% vest evenly over 36 months thereafter. The following assumptions were used in the Black-Scholes option pricing model: September 30, December 31, Risk-free interest rate 3.95% - 4.19 % 3.39% -3.86 % Expected life 10 years 10 years Expected dividend rate 0.00 % 0.00 % Expected volatility 100 % 100 % Forfeiture rate 0.00 % 0.00 % The continuity of stock options for the nine months ended September 30, 2024, and December 31, 2023, is summarized below: Number of Weighted Outstanding, December 31, 2022 1,366,167 1.08 Granted 234,000 5.00 Forfeited (14,583 ) 0.60 Exercised (62,500 ) 0.60 Outstanding, December 31, 2023 1,523,084 1.71 Granted 92,500 1.54 Forfeited (394,990 ) 2.20 Exercised - - Outstanding, September 30, 2024 1,220,594 1.52 As of September 30, 2024, the following options were outstanding, entitling the holders thereof the right to purchase one common stock for each option held as follows: Outstanding Vested Expiry date Weighted average 816,677 763,203 February 8, 2031 0.60 35,417 35,417 February 27, 2031 0.60 5,000 3,021 April 25, 2032 0.60 16,000 9,000 June 1, 2032 1.34 16,000 8,000 September 30, 2032 1.34 80,000 40,000 September 30, 2032 5.00 10,000 4,792 October 15, 2032 1.34 5,000 2,292 November 1, 2032 5.00 10,000 3,958 March 2, 2033 5.00 50,000 16,666 April 16, 2033 5.00 80,000 28,333 May 1, 2033 5.00 10,000 3,125 June 27, 2033 5.00 1,500 438 July 1, 2033 5.00 5,000 - February 12, 2034 5.00 80,000 - March 5, 2034 1.00 1,220,594 918,245 As of September 30, 2024, and December 31, 2023, the weighted average life of stock options outstanding was 7.03 years and 7.84 years, respectively. During the nine months ended September 30, 2024, and 2023, the Company recorded $57,521 and $346,549, respectively, in share-based compensation expense, of which $53,977 and $3,543, and $337,551 and $8,998, respectively is included in office and administration and research and development, respectively.

Related Party Transactions

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions	15. Related Party Transactions Related parties consist of the following individuals and corporations: ● Braeden Lichti, Non-executive Chairman, significant shareholder through BWL Investments Ltd. ● Jordan Plews, Director and CEO of Skincare and BioSciences, significant shareholder through JP Bio Consulting LLC ● Graydon Bensler, Director and CEO, CFO of Elevai ● Tim Sayed, Former Chief Medical Officer and Former Director (resigned August 1, 2024) ● Brenda Buechler, Former Chief Marketing Officer (effective June 20, 2024) ● Christoph Kraneiss, Former Chief Commercial Officer (effective June 20, 2024) ● Jeffrey Parry, Director (appointed June 1, 2023) ● Julie Daley, Director (appointed June 1, 2023) ● Crystal Muilenburg, Former Director (appointed June 1, 2023, resigned February 29, 2024) ● George Kovalyov, Director (appointed March 1, 2024) ● GB Capital Ltd., controlled by Graydon Bensler ● JP Bio Consulting LLC, significant shareholder and controlled by Jordan Plews ● BWL Investments Ltd., significant shareholder and controlled by Braeden Lichti ● Northstrive Companies Inc., controlled by Braeden Lichti Key management personnel include those persons having authority and responsibility for planning, directing, and controlling the activities of the Company as a whole. The Company has determined that key management personnel consist of members of the Company’s Board of Directors, corporate officers, and individuals with more than 10% control. Remuneration attributed to key management personnel are summarized as follows: Three months Three months Nine months Nine months Consulting fees $ 101,100 51,250 261,933 153,750 Salaries 67,353 159,874 445,009 476,126 Share-based compensation 30,764 124,994 (1,819 ) 247,348 $ 199,217 336,118 705,123 877,224 During the nine months ended September 30, 2024, the Company incurred consulting fees of $150,833 (September 30, 2023 - $63,750) to GB Capital Ltd., a company controlled by Graydon Bensler, CEO, CFO and Director. In addition, the Company incurred consulting fees of $111,100 (September 30, 2023 - $90,000) to Northstrive Companies Inc., a company controlled by Braeden Litchi, the Company’s Chairman. Jordan Plews, Director and CEO of Skincare and BioSciences, earned a Salary of $189,385 and $168,050 respectively during the nine months ended September 30, 2024, and 2023 (includes employer taxes of $21,051 and $18,050, respectively). Brenda Buechler, former Chief Marketing Officer, earned a Salary of $132,807 and $159,950, respectively during the nine months ended September 30, 2024, and 2023 (includes employer taxes of $14,297 and $17,446 respectively). Christoph Kraneiss, former Chief Commercial Officer, earned a Salary of $122,818 and $148,131, respectively during the nine months ended September 30, 2024, and 2023 (includes employer taxes of $10,639 and $13,131, respectively). During the nine months ended September 30, 2024, and 2023, the Company issued the following stock options to related parties: On March 1, 2024, the Company granted 80,000 stock options to directors of the company with a contractual life of 10 years and exercise price of $1.00 per share of common stock. These stock options were valued at $45,986 using the Black-Scholes Option Pricing Model. The options vest 25% on the first anniversary of the grant date and the remaining 75% vest evenly over 36 months thereafter. Details of the fair value granted to each related party in the current and prior periods, and the related expense recorded for the nine months ended September 30, 2024, and 2023 is as follow: Nine Months Nine Months Fair value of Braeden Lichti, Chairman $ 1,894 $ 5,398 $ 50,995 Graydon Bensler, CEO, CFO and Director 1,897 5,398 50,995 Jordan Plews, Director and CEO of Skincare and BioSciences 1,897 5,398 50,995 Tim Sayed, Former Chief Medical Officer and Former Director 1 (4,291 ) 5,398 50,995 Jeffrey Parry, Director 18,564 21,177 107,669 Crystal Muilenburg, Former Director 1 (41,668 ) 46,725 210,245 Julie Daley, Director 69,111 56,022 210,245 George Kovalyov, Director 18,144 - 52,845 Brenda Buechler, Former Chief Marketing Officer 1 (36,918 ) - 143,671 Christoph Kraneiss, Former Chief Commercial Officer 1 (30,449 ) - 121,243 $ (1,819 ) $ 145,516 $ 1,049,898 1 354,990 options of related parties were forfeited in the nine months ended September 30, 2024. As of September 30, 2024, and December 31, 2023, the Company had $22,217 and $22,455, respectively due to companies controlled by Braeden Lichti, of which $22,217 and $22,455, respectively, is unsecured, non-interest bearing and are due on demand. Additionally, the Company drew $200,000 on a line of credit provided by a company controlled by Braeden Lichti during the nine months ended September 30, 2024. The line of credit incurs interest at a rate of 20% per annum on the outstanding principal. During the nine months ended September 30, 2024, $6,833 in interest had accrued on this line of credit. As of September 30, 2024, the Company had $80,368 (December 31, 2023 - $34,378) in consulting fees due to Graydon Bensler, CEO, CFO and Director, $49,500 (December 31, 2023 - $15,143) due to companies controlled by Braeden Lichti, and $ Nil Nil Nil

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2024
Commitments and Contingencies [Abstract]
Commitments and Contingencies	16. Commitments and Contingencies There were no As of March 18, 2024, the Company has voluntarily stopped sale of its products in Canada following a communication from Health Canada regarding the way the Company’s products are marketed in Canada. The Company is working with Canadian regulatory and legal counsel to explore options to rectify the issues raised. On April 30, 2024, the Company's appointed Canadian distributor terminated the existing distribution agreement.

Concentrations

Concentrations	9 Months Ended
Concentrations	Sep. 30, 2024
Concentrations [Abstract]
Concentrations	17. Concentrations Customers For the nine months ended September 30, 2024, no single customer represented 10% or more of the Company's revenue. During the nine-month period ended September 30, 2023, the Company recorded 14% of its revenue from its largest customers. The Company’s largest customer, representing $139,149 of revenue, relates to sales to a wholesaler during the period. Suppliers During the nine months ended September 30, 2024, and 2023, the Company had 3 key suppliers that represented approximately 78% and 3 key suppliers that represented approximately 66%, respectively, of the cost incurred in the purchase and production of inventory. The table below represents a breakdown of each supplier as a percentage of the cost incurred. (Suppliers are shown from largest to smallest and do not necessarily represent the same suppliers period over period): Nine Months Nine Months Supplier 1 37 % 26 % Supplier 2 29 % 23 % Supplier 3 12 % 17 % 78 % 66 % The Company continually evaluates the performance of its suppliers and the availability of alternatives to substitute or supplement its inventory production supply chain. The Company believes that a breakdown in supply from one of its key suppliers would be overcome in a short amount of time given the availability of alternatives.

Subsequent Events

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	18. Subsequent Events Management has evaluated events subsequent to the year ended September 30, 2024, up to November 13, 2024, for transactions and other events that may require adjustment of and/or disclosure in the consolidated financial statements. Issuance of commons shares On November 1, 2024, the Company issued 612,500 shares to a consultant in relation to the acquisition of the License #2 IPR&D asset (Note 8). Exercise of Series B Warrants As of November 13, 2024, 155,890,910 Series B Warrants have been exercised under the alternative cashless exercise feature into 467,672,730 shares of common stock, resulting in 32,303,390 unexercised Series B Warrants.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended		9 Months Ended
Pay vs Performance Disclosure - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (1,501,257)	$ (783,047)	$ (4,310,998)	$ (3,143,601)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
Accounting Policies, by Policy (Policies)	Sep. 30, 2024
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation These unaudited condensed consolidated financial statements have been prepared in accordance with rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and generally accepted accounting principles in the United States (“U.S. GAAP”) for interim financial information and are expressed in United States dollars. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, we have included all adjustments considered necessary for a fair presentation and such adjustments are of a normal recurring nature. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the years ended December 31, 2023, and 2022. The results of operations for the nine months ended September 30, 2024, are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2024.
Principles of Consolidation	Principles of Consolidation The unaudited condensed consolidated financial statements include the account of Elevai, and its 100% owned subsidiaries, Elevai Research Inc., Skincare, and BioSciences. All intercompany accounts, transactions and profits were eliminated in the unaudited condensed consolidated financial statements.
Use of Estimates	Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to revenue recognition, the collectability of receivables, valuation of inventory, fair value of derivative liabilities and stock options, useful lives and recoverability of long-lived assets, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying value of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from those estimates. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the unaudited condensed consolidated financial statements in the period they are determined.
Foreign Currency Translation	Foreign Currency Translation The Company’s functional and reporting currency is the U.S. dollar. The functional currency of Elevai Research Inc. is the Canadian dollar. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Non-monetary assets, liabilities, and items recorded in income arising from transactions denominated in foreign currencies are translated at rates of exchange in effect at the date of the transaction. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in the determination of income. The accounts of Elevai Research Inc. are translated to U.S. dollars using the current rate method. Accordingly, assets and liabilities are translated into U.S. dollars at the period-end exchange rate while revenues and expenses are translated at the average exchange rates during the period. Related exchange gains and losses are included in a separate component of stockholders’ equity as accumulated other comprehensive income (loss).
Intangible Assets	Intangible Assets In accordance with ASC 350 “Intangibles—Goodwill and Other”, intangible assets are recorded at cost less accumulated amortization. They are depreciated using the straight-line method over their estimated useful lives, which reflect the period over which economic benefits are expected to be realized. In accordance with ASC 730 “Research and development costs”, an acquired in-process researched and development (“IPR&D”) intangible asset with an alternative future use is capitalized, in accordance with ASC 350, and amortized over its useful life. Although IPR&D assets are likely to be finite-lived, amortization does not begin until the research and development projects are completed. In accordance with the IPR&D asset purchase agreement, the Company is required to meet development milestones starting with the initiation of a pre-clinical IND-enabling study within 2 years of the acquisition date, and ending with obtaining marketing approval from the FDA within 9 years of the acquisition date. Management assesses impairment indicators at each reporting period end. The estimated useful lives of intangible assets are generally as follows: License #1 10-year straight-line License #2 IPR&D project not yet complete
Accounting for Freestanding Instruments Issued Together	Accounting for Freestanding Instruments Issued Together The Company accounts for multiple instruments issued together in accordance with ASC 470 “Debt”, ASC 480 “Distinguishing Liabilities from Equity” and ASC 505 “Equity”. The Company first identifies all freestanding instruments. When multiple freestanding instruments are issued in a single transaction, the total proceeds from the transaction are allocated among the individual freestanding instruments identified based on their relative fair values at issuance. Transaction costs that are directly attributable to the issuance of both debt and equity are allocated between the liability and equity components based on their relative fair values.
New Accounting Standards	New Accounting Standards Recently Adopted Accounting Standards In March 2022, the FASB issued ASU 2022-02, ASC Subtopic 326 “Credit Losses”: Troubled Debt Restructurings and Vintage Disclosures. Since the issuance of Accounting Standards Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, the Board has provided resources to monitor and assist stakeholders with the implementation of Topic 326 (“Update”). Post-Implementation Review (PIR) activities have included forming a Credit Losses Transition Resource Group, conducting outreach with stakeholders of all types, developing educational materials and staff question-and-answer guidance, conducting educational workshops, and performing an archival review of financial reports. ASU No. 2022-02 is effective for annual and interim periods beginning after December 15, 2022. The adoption of this standard did not have a significant impact on the Company’s unaudited condensed consolidated financial statements. In June 2022, the FASB issued ASU 2022-03, ASC Subtopic 820 “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”. The FASB is issuing this Update (1) to clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. Stakeholders asserted that the language in the illustrative example resulted in diversity in practice on whether the effects of a contractual restriction that prohibits the sale of an equity security should be considered in measuring that equity security’s fair value. Some stakeholders apply a discount to the price of an equity security subject to a contractual sale restriction, whereas other stakeholders consider the application of a discount to be inappropriate under the principles of Topic 820. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The adoption of this standard did not have a significant impact on the Company’s unaudited condensed consolidated financial statements. Recently Issued Accounting Standards The Company assesses the adoption impacts of recently issued, but not yet effective, accounting standards by the Financial Accounting Standards Board on the Company’s unaudited condensed consolidated financial statements. There are no recently issued accounting standards which may have effect on the Company’s unaudited condensed consolidated financial statements

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
Summary of Significant Accounting Policies (Tables)	Sep. 30, 2024
Summary of Significant Accounting Policies [Abstract]
Schedule of Estimated Useful Lives of Intangible Assets	The estimated useful lives of intangible assets are generally as follows: License #1 10-year straight-line License #2 IPR&D project not yet complete

Receivables (Tables)

Receivables (Tables)	9 Months Ended
Receivables (Tables)	Sep. 30, 2024
Receivables [Abstract]
Schedule of Receivables	As of September 30, 2024, receivables consisted of the following: September 30, December 31, Trade receivable $ 16,889 $ 33,089 Sales taxes receivable 10,998 3,072 $ 27,887 $ 36,161

Prepaids and Deposits (Tables)

Prepaids and Deposits (Tables)	9 Months Ended
Prepaids and Deposits (Tables)	Sep. 30, 2024
Prepaids and Deposits [Abstract]
Schedule of Prepaid and Deposits	As of September 30, 2024, and December 31, 2023, prepaid and deposits consisted of the following: September 30, December 31, Prepaid expenses $ 651,984 $ 957,645 Deposits 135,864 113,893 $ 787,848 $ 1,071,538 Prepaids and deposits - current 787,848 1,060,765 Deposits- non-current - 10,773

Inventory (Tables)

Inventory (Tables)	9 Months Ended
Inventory (Tables)	Sep. 30, 2024
Inventory [Abstract]
Schedule of Inventory	As of September 30, 2024, and December 31, 2023, inventory consisted of the following: September 30, December 31, Raw materials $ 439,328 $ 279,514 Work in progress 289,113 147,906 Finished goods 257,980 68,247 $ 986,421 $ 495,667

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
Property and Equipment (Tables)	Sep. 30, 2024
Property and Equipment [Abstract]
Schedule of Property and Equipment	Equipment Furniture Computers Total Cost Balance, December 31, 2022 $ 50,516 $ 8,365 $ 2,759 $ 61,640 Additions 2,658 8,533 - 11,191 Foreign currency translation - - 61 61 Balance, December 31, 2023 $ 53,174 $ 16,898 $ 2,820 $ 72,892 Additions 9,160 - - 9,160 Foreign currency translation - - (54 ) (54 ) Balance, September 30, 2024 $ 62,334 $ 16,898 $ 2,766 $ 81,998 Accumulated depreciation Balance, December 31, 2022 $ 7,052 $ 548 $ 505 $ 8,105 Depreciation 8,680 2,414 555 11,649 Foreign currency translation - - 19 19 Balance, December 31, 2023 $ 15,732 $ 2,962 $ 1,079 $ 19,773 Depreciation 7,492 1,811 412 9,715 Foreign currency translation - - (18 ) (18 ) Balance, September 30, 2024 $ 23,224 $ 4,773 $ 1,473 $ 29,470 Net book value December 31, 2023 $ 37,442 $ 13,936 $ 1,741 $ 53,119 September 30, 2024 $ 39,110 $ 12,125 $ 1,293 $ 52,528

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
Intangible Assets (Tables)	Sep. 30, 2024
Intangible Assets [Abstract]
Schedule of the Black-Scholes Option Pricing Model	The following assumptions were used in the Black-Scholes option pricing model: Initial Risk-free interest rate 5.12-5.44% Expected life 0.5-1 years Expected dividend rate 0.00% Expected volatility 100%
Schedule of Intangible Assets	License #1 License #2 Total Cost Balance, December 31, 2023 $ - - - Additions 861,452 2,023,097 2,884,549 Balance, September 30, 2024 $ 861,452 2,023,097 2,884,549 Accumulated amortization Balance, December 31, 2023 $ - - - Additions 61,019 - 61,019 Balance, September 30, 2024 $ 61,019 - 61,019 Net Book value – September 30, 2024 $ 800,433 2,023,097 2,823,530

Operating Lease (Tables)

Operating Lease (Tables)	9 Months Ended
Operating Lease (Tables)	Sep. 30, 2024
Operating Lease [Abstract]
Schedule of Lease Cost	The lease cost has been allocated as follows based on the square footage of each property location. September 30, September 30, Office space, recorded in office and administration $ 90,863 $ 74,640 Lab space, recorded in research and development 18,688 23,705 Lab space, capitalized to production of inventory 9,671 4,655 $ 119,222 $ 103,000
Schedule of Future Minimum Lease Payments	Future minimum lease payments under the Company’s operating lease that have an initial non-cancelable lease term in excess of one year at September 30, 2024, are as follows: As of September 30, 2024 Total 2024 40,430 2025 67,384 Thereafter - 107,814 Less: Imputed interest (4,505 ) Operating lease liability 103,309 Operating lease lability – current 103,309 Operating lease lability – non-current $ -

Accounts Payable and Accrued _2

Accounts Payable and Accrued Liabilities (Tables)	9 Months Ended
Accounts Payable and Accrued Liabilities (Tables)	Sep. 30, 2024
Accounts Payable and Accrued Liabilities [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	As of September 30, 2024, and December 31, 2023, accounts payable and accrued liabilities consisted of the following: September 30, December 31, Accounts payable $ 1,078,624 $ 596,147 Accrued liabilities 137,567 73,228 $ 1,216,191 $ 669,375

Consideration Payable (Tables)

Consideration Payable (Tables)	9 Months Ended
Consideration Payable (Tables)	Sep. 30, 2024
Consideration Payable [Abstract]
Schedule of Consideration Payable	Consideration Outstanding, December 31, 2023 $ - Additions 861,452 Payment (50,000 ) Accretion expense 58,259 Outstanding, September 30, 2024 $ 869,711 Consideration payable – current 350,000 Consideration payable – non-current $ 519,711

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	9 Months Ended
Derivative Liabilities (Tables)	Sep. 30, 2024
Derivative Liabilities [Line Items]
Schedule of Common Stock Purchase Derivative Liability Warrants	A continuity of the Company’s common stock purchase derivative liability warrants is as follows: Derivative Outstanding, December 31, 2022 $ 68,455 Addition of new derivatives during IPO 229,437 Change in fair value of derivative liabilities 71,266 Outstanding, December 31, 2023 $ 369,158 Change in fair value of derivative liabilities (367,277 ) Outstanding, September 30, 2024 $ 1,881
Schedule of Black-Scholes Option Pricing Model	The following assumptions were used in the Black-Scholes option pricing model: Initial Risk-free interest rate 5.12-5.44% Expected life 0.5-1 years Expected dividend rate 0.00% Expected volatility 100%
Derivative liabilities [Member]
Derivative Liabilities [Line Items]
Schedule of Black-Scholes Option Pricing Model	The following assumptions were used in the Black-Scholes option pricing model: September 30, December 31, November 21, December 31, July 15, Risk-free interest rate 3.58 % 3.84 - 4.01% 4.41 % 4.73 % 3.12 % Expected life 1 2.57 – 4.15 years 3.32 – 4.90 years 5 years 0.75 years 0.6 years Expected dividend rate 0 % 0 % 0.00 % 0.00 % 0.00 % Expected volatility 100 % 100 % 100 % 100 % 100 % 1 On April 28, 2023, the Company amended the warrant agreements for the 231,828 derivative liability warrants outstanding. The amendment removed the clause to automatically convert warrants to shares on IPO date and all warrants were given an expiry date of April 27, 2027. This led to an increase in the expected life input in the Black-Scholes model as of December 31, 2023, compared to December 31, 2022, when the Company used the expected IPO date to calculate the expected life of the warrants.
Schedule of Derivative Liability Warrants Outstanding	As of September 30, 2024, the following derivative liability warrants were outstanding: Outstanding Expiry date 1 Weighted average 75,840 April 27, 2027 2.01 63,037 April 27, 2027 2.01 80,388 April 27, 2027 2.01 12,563 April 27, 2027 2.01 75,000 November 21, 2028 4.00 306,828 2.50 1 On April 28, 2023, the Company amended the warrant agreements for the 231,828 derivative liability warrants outstanding. The amendment removed the clause to automatically convert warrants to shares on IPO date and all warrants were given an expiry date of April 27, 2027. This led to an increase in the expected life input in the Black-Scholes model as of December 31, 2023, compared to December 31, 2022, when the Company used the expected IPO date to calculate the expected life of the warrants.

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
Notes Payable (Tables)	Sep. 30, 2024
Notes Payable [Abstract]
Schedule of Notes Payable	A continuity of the Company’s Notes Payable during the nine months ended September 30, 2024 is as follows: Notes Outstanding, December 31, 2023 $ - Fair value of Notes issued 622,239 Transaction costs (85,558 ) Interest accretion 613,319 Repayment (1,150,000 ) Outstanding, September 30, 2024 $ -

Equity (Tables)

Equity (Tables)	9 Months Ended
Equity (Tables)	Sep. 30, 2024
Equity [Line Items]
Schedule of Equity Warrants	As of September 30, 2024, the following equity warrants were outstanding: Outstanding Expiry date Weighted average 250,000 August 28, 2026 3.00 99,998 March 12, 2027 3.00 28,571,425 1 October 30, 2029 0.38 1 28,571,425 2 April 30, 2027 0.38 2 1,428,571 March 24, 2028 0.34 58,921,419 0.39
Schedule of Black-Scholes Option Pricing Model	The following assumptions were used in the Black-Scholes option pricing model: Initial Risk-free interest rate 5.12-5.44% Expected life 0.5-1 years Expected dividend rate 0.00% Expected volatility 100%
Schedule of Stock Options	The continuity of stock options for the nine months ended September 30, 2024, and December 31, 2023, is summarized below: Number of Weighted Outstanding, December 31, 2022 1,366,167 1.08 Granted 234,000 5.00 Forfeited (14,583 ) 0.60 Exercised (62,500 ) 0.60 Outstanding, December 31, 2023 1,523,084 1.71 Granted 92,500 1.54 Forfeited (394,990 ) 2.20 Exercised - - Outstanding, September 30, 2024 1,220,594 1.52
Schedule of Right To Purchase One Common Stock Option Held	As of September 30, 2024, the following options were outstanding, entitling the holders thereof the right to purchase one common stock for each option held as follows: Outstanding Vested Expiry date Weighted average 816,677 763,203 February 8, 2031 0.60 35,417 35,417 February 27, 2031 0.60 5,000 3,021 April 25, 2032 0.60 16,000 9,000 June 1, 2032 1.34 16,000 8,000 September 30, 2032 1.34 80,000 40,000 September 30, 2032 5.00 10,000 4,792 October 15, 2032 1.34 5,000 2,292 November 1, 2032 5.00 10,000 3,958 March 2, 2033 5.00 50,000 16,666 April 16, 2033 5.00 80,000 28,333 May 1, 2033 5.00 10,000 3,125 June 27, 2033 5.00 1,500 438 July 1, 2033 5.00 5,000 - February 12, 2034 5.00 80,000 - March 5, 2034 1.00 1,220,594 918,245
Equity Option [Member]
Equity [Line Items]
Schedule of Black-Scholes Option Pricing Model	The following assumptions were used in the Black-Scholes option pricing model: September 30, December 31, Risk-free interest rate 3.95% - 4.19 % 3.39% -3.86 % Expected life 10 years 10 years Expected dividend rate 0.00 % 0.00 % Expected volatility 100 % 100 % Forfeiture rate 0.00 % 0.00 %

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
Related Party Transactions (Tables)	Sep. 30, 2024
Related Party Transactions [Line Items]
Schedule of Fair Value of the Options Granted to Each Individual and the Related Expense	Remuneration attributed to key management personnel are summarized as follows: Three months Three months Nine months Nine months Consulting fees $ 101,100 51,250 261,933 153,750 Salaries 67,353 159,874 445,009 476,126 Share-based compensation 30,764 124,994 (1,819 ) 247,348 $ 199,217 336,118 705,123 877,224
Related Party [Member]
Related Party Transactions [Line Items]
Schedule of Fair Value of the Options Granted to Each Individual and the Related Expense	Details of the fair value granted to each related party in the current and prior periods, and the related expense recorded for the nine months ended September 30, 2024, and 2023 is as follow: Nine Months Nine Months Fair value of Braeden Lichti, Chairman $ 1,894 $ 5,398 $ 50,995 Graydon Bensler, CEO, CFO and Director 1,897 5,398 50,995 Jordan Plews, Director and CEO of Skincare and BioSciences 1,897 5,398 50,995 Tim Sayed, Former Chief Medical Officer and Former Director 1 (4,291 ) 5,398 50,995 Jeffrey Parry, Director 18,564 21,177 107,669 Crystal Muilenburg, Former Director 1 (41,668 ) 46,725 210,245 Julie Daley, Director 69,111 56,022 210,245 George Kovalyov, Director 18,144 - 52,845 Brenda Buechler, Former Chief Marketing Officer 1 (36,918 ) - 143,671 Christoph Kraneiss, Former Chief Commercial Officer 1 (30,449 ) - 121,243 $ (1,819 ) $ 145,516 $ 1,049,898 1 354,990 options of related parties were forfeited in the nine months ended September 30, 2024.

Concentrations (Tables)

Concentrations (Tables)	9 Months Ended
Concentrations (Tables)	Sep. 30, 2024
Concentrations [Abstract]
Schedule of Suppliers Percentage of Cost	The table below represents a breakdown of each supplier as a percentage of the cost incurred. (Suppliers are shown from largest to smallest and do not necessarily represent the same suppliers period over period): Nine Months Nine Months Supplier 1 37 % 26 % Supplier 2 29 % 23 % Supplier 3 12 % 17 % 78 % 66 %

Organization and Nature of Op_2

Organization and Nature of Operations (Details)	Jun. 09, 2020
Elevai Labs Inc. [Member]
Organization and Nature of Operations [Line Items]
Owned subsidiary percentage	100%

Going Concern (Details)

Going Concern (Details) - USD ($)	3 Months Ended		9 Months Ended
Going Concern (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Going Concern [Abstract]
Net working capital	$ 6,097,404		$ 6,097,404		$ 3,622,091
Accumulated deficit	(11,334,888)		(11,334,888)		$ (7,023,890)
Net loss	$ (1,501,257)	$ (783,047)	(4,310,998)	$ (3,143,601)
Cash flows for operating activities			$ (3,486,435)	$ (2,168,661)

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details)	Sep. 30, 2024
Prinicipal of Consolidation [Member]
Summary of Significant Accounting Policies [Line Items]
Owners percentage	100%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Intangible Assets - License [Member]	9 Months Ended
	Sep. 30, 2024
Schedule of Estimated Useful Lives of Intangible Assets [Line Items]
License #1	10 years
License #2	IPR&D project not yet complete

Receivables (Details)

Receivables (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Receivables [Abstract]
Provision for credit losses

Receivables (Details) - Schedul

Receivables (Details) - Schedule of Receivables - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Receivables [Abstract]
Trade receivable	$ 16,889	$ 33,089
Sales taxes receivable	10,998	3,072
Total	$ 27,887	$ 36,161

Prepaids and Deposits (Details)

Prepaids and Deposits (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Schedule of Prepaid And Deposits [Abstract]
Long term lease		$ 10,773

Prepaids and Deposits (Detail_2

Prepaids and Deposits (Details) - Schedule of Prepaid and Deposits - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Schedule of Prepaid And Deposits [Abstract]
Prepaid expenses	$ 651,984	$ 957,645
Deposits	135,864	113,893
Prepaid and deposits	787,848	1,071,538
Prepaids and deposits - current	787,848	1,060,765
Deposits- non-current		$ 10,773

Inventory (Details)

Inventory (Details) - USD ($)	9 Months Ended
Inventory (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Inventory [Abstract]
Cost of sales	$ 214,272	$ 193,805
Marketing and promotion expense	134,000	$ 96,184
Allowance for inventory

Inventory (Details) - Schedule

Inventory (Details) - Schedule of Inventory - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Schedule of Inventory [Abstract]
Raw materials	$ 439,328	$ 279,514
Work in progress	289,113	147,906
Finished goods	257,980	68,247
Total inventory	$ 986,421	$ 495,667

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Property and Equipment [Abstract]
Capitalized depreciation	$ 1,936	$ 914

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of Property and Equipment - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Cost
Cost, Balance beginning	$ 72,892	$ 61,640
Cost, Additions	9,160	11,191
Cost, Foreign currency translation	(54)	61
Cost, Balance ending	81,998	72,892
Accumulated depreciation
Accumulated depreciation, Balance beginning	19,773	8,105
Depreciation	9,715	11,649
Accumulated depreciation, Foreign currency translation	(18)	19
Accumulated depreciation, Balance ending	29,470	19,773
Net book value	52,528	53,119
Equipment [Member]
Cost
Cost, Balance beginning	53,174	50,516
Cost, Additions	9,160	2,658
Cost, Foreign currency translation
Cost, Balance ending	62,334	53,174
Accumulated depreciation
Accumulated depreciation, Balance beginning	15,732	7,052
Depreciation	7,492	8,680
Accumulated depreciation, Foreign currency translation
Accumulated depreciation, Balance ending	23,224	15,732
Net book value	39,110	37,442
Furniture and Fixtures [Member]
Cost
Cost, Balance beginning	16,898	8,365
Cost, Additions		8,533
Cost, Foreign currency translation
Cost, Balance ending	16,898	16,898
Accumulated depreciation
Accumulated depreciation, Balance beginning	2,962	548
Depreciation	1,811	2,414
Accumulated depreciation, Foreign currency translation
Accumulated depreciation, Balance ending	4,773	2,962
Net book value	12,125	13,936
Computers [Member]
Cost
Cost, Balance beginning	2,820	2,759
Cost, Additions
Cost, Foreign currency translation	(54)	61
Cost, Balance ending	2,766	2,820
Accumulated depreciation
Accumulated depreciation, Balance beginning	1,079	505
Depreciation	412	555
Accumulated depreciation, Foreign currency translation	(18)	19
Accumulated depreciation, Balance ending	1,473	1,079
Net book value	$ 1,293	$ 1,741

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)						9 Months Ended
Intangible Assets (Details) - USD ($)	Feb. 02, 2025	Nov. 01, 2024	Aug. 01, 2024	May 03, 2024	Jan. 15, 2024	Sep. 30, 2024	Dec. 31, 2023
Intangible Assets [Line Items]
Intangible assets license term					10 years
Purchase price					$ 1,000,000
Intangible asset payable					600,000
Intangible assets						$ 2,884,549
Consideration paid						$ 400,000
Common shares (in Shares)						950,000
Common shares value						$ 492,850
Fair value adjustment						$ 173,100
Shares were fully vested (in Shares)		612,500	612,500	612,500		2,450,000
Pharmaceutical [Member]
Intangible Assets [Line Items]
Fair value adjustment						$ 599,863
Legal fees						12,320
Acquiring license						$ 1,117,771
License [Member]
Intangible Assets [Line Items]
Intangible assets license term						10 years
Intangible asset payable					50,000
Intangible assets						$ 861,452
License #2 (IPR&D asset) [Member]
Intangible Assets [Line Items]
Intangible assets						$ 2,023,097
Consideration Payable [Member]
Intangible Assets [Line Items]
Interest rate of percentage						11.75%
Consideration Payable [Member] \| License [Member]
Intangible Assets [Line Items]
Interest rate of percentage						11.75%
March 15, 2025 [Member]
Intangible Assets [Line Items]
Intangible asset payable					$ 350,000
Forecast [Member]
Intangible Assets [Line Items]
Shares were fully vested (in Shares)	612,500

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of the Black-Scholes Option Pricing Model - Finite-Lived Intangible Assets [Member]	9 Months Ended
	Sep. 30, 2024
Schedule of the Black-Scholes Option Pricing Model [Line Items]
Expected dividend rate	0%
Expected volatility	100%
Minimum [Member]
Schedule of the Black-Scholes Option Pricing Model [Line Items]
Risk-free interest rate	5.12%
Expected life	6 months
Maximum [Member]
Schedule of the Black-Scholes Option Pricing Model [Line Items]
Risk-free interest rate	5.44%
Expected life	1 year

Intangible Assets (Details) -_2

Intangible Assets (Details) - Schedule of Intangible Assets - USD ($)	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Cost
Balance, December 31, 2023
Additions	2,884,549
Balance, September 30, 2024	2,884,549
Accumulated amortization
Balance, December 31, 2023
Additions	61,019
Balance, September 30, 2024	61,019
Net Book value – September 30, 2024	2,823,530
License #1 [Member]
Cost
Balance, December 31, 2023
Additions	861,452
Balance, September 30, 2024	861,452
Accumulated amortization
Balance, December 31, 2023
Additions	61,019
Balance, September 30, 2024	61,019
Net Book value – September 30, 2024	800,433
License #2 (IPR&D asset) [Member]
Cost
Balance, December 31, 2023
Additions	2,023,097
Balance, September 30, 2024	2,023,097
Accumulated amortization
Balance, December 31, 2023
Additions
Balance, September 30, 2024
Net Book value – September 30, 2024	$ 2,023,097

Operating Lease (Details)

Operating Lease (Details) - USD ($)			9 Months Ended
Operating Lease (Details) - USD ($)	Jul. 03, 2023	Jul. 01, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Operating Lease [Line Items]
Increase lease liability		$ 47,986
Discount rate of lease liability		11.50%
Percentage of discount rate		8%
Operating lease			$ 119,222	$ 103,000
Security deposit			$ 10,773		$ 10,773
Remaining lease term			8 months 1 day		1 year 5 months 1 day
Minimum [Member]
Operating Lease [Line Items]
Rent increased	$ 10,773
Maximum [Member]
Operating Lease [Line Items]
Rent increased	$ 13,477

Operating Lease (Details) - Sch

Operating Lease (Details) - Schedule of Lease Cost - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Schedule of Lease Cost [Abstract]
Office space, recorded in office and administration	$ 90,863	$ 74,640
Lab space, recorded in research and development	18,688	23,705
Lab space, capitalized to production of inventory	9,671	4,655
Operating lease	$ 119,222	$ 103,000

Operating Lease (Details) - S_2

Operating Lease (Details) - Schedule of Future Minimum Lease Payments - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Schedule of Future Minimum Lease Payments [Abstract]
2024	$ 40,430
2025	67,384
Thereafter
Total lease payment	107,814
Less: Imputed interest	(4,505)
Operating lease liability	103,309
Operating lease lability – current	103,309	$ 145,000
Operating lease lability – non-current		$ 65,489

Accounts Payable and Accrued _3

Accounts Payable and Accrued Liabilities (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Schedule of Accounts Payable and Accrued Liabilities [Abstract]
Accounts payable	$ 1,078,624	$ 596,147
Accrued liabilities	137,567	73,228
Total	$ 1,216,191	$ 669,375

Consideration Payable (Details)

Consideration Payable (Details) - USD ($)		9 Months Ended
Consideration Payable (Details) - USD ($)	Jan. 15, 2024	Sep. 30, 2024
Consideration Payable [Line Items]
Fair value of payments	$ 950,000
Discount on the consideration payable		$ 138,548
Consideration Payable [Member]
Consideration Payable [Line Items]
Percentage of consideration payable		11.75%

Consideration Payable (Detail_2

Consideration Payable (Details) - Schedule of Consideration Payable - USD ($)	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Schedule of Consideration Payable [Abstract]
Outstanding, December 31, 2023
Consideration payable – current	350,000
Consideration payable – non-current	519,711
Additions	861,452
Payment	(50,000)
Accretion expense	58,259
Outstanding, September 30, 2024	$ 869,711

Derivative Liabilities (Details

Derivative Liabilities (Details) - $ / shares	Nov. 21, 2023	Sep. 30, 2024	Sep. 24, 2024	Dec. 31, 2023	Apr. 28, 2023	Jul. 15, 2022
Derivative Liabilities [Line Items]
Warrants purchase						231,828
Warrant exercise price (in Dollars per share)			$ 0.28			$ 2.01
Price per share (in Dollars per share)	$ 4
Warrants maturity date					Apr. 27, 2027
Derivative liability warrants outstanding term		3 years 9 months 21 days		2 years 9 months 21 days
Derivative liability warrants outstanding					231,828
IPO warrants [Member]
Derivative Liabilities [Line Items]
Warrants issued	75,000
Warrants maturity date	Nov. 21, 2028
Derivative Liability Warrants [Member]
Derivative Liabilities [Line Items]
Derivative liability warrants outstanding term		2 years 11 months 15 days		3 years 8 months 15 days

Derivative Liabilities (Detai_2

Derivative Liabilities (Details) - Schedule of Common Stock Purchase Derivative Liability Warrants - Warrant [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Derivative [Line Items]
Derivative liabilities outstanding, Ending balance	$ 1,881	$ 369,158	$ 68,455
Addition of new derivatives during IPO		229,437
Change in fair value of derivative liabilities	$ (367,277)	$ 71,266

Derivative Liabilities (Detai_3

Derivative Liabilities (Details) - Schedule of Black-Scholes Option Pricing Model - Black-Scholes Option Pricing Model [Member]						9 Months Ended
		Dec. 31, 2023	Nov. 21, 2023	Dec. 31, 2022	Jul. 15, 2022	Sep. 30, 2024
Derivative Liabilities (Details) - Schedule of Black-Scholes Option Pricing Model [Line Items]
Risk-free interest rate			4.41%	4.73%	3.12%	3.58%
Expected life	[1]		5 years	9 months	7 months 6 days
Expected dividend rate		0%	0%	0%	0%	0%
Expected volatility		100%	100%	100%	100%	100%
Minimum [Member]
Derivative Liabilities (Details) - Schedule of Black-Scholes Option Pricing Model [Line Items]
Risk-free interest rate		3.84%
Expected life	[1]	3 years 3 months 25 days				2 years 6 months 25 days
Maximum [Member]
Derivative Liabilities (Details) - Schedule of Black-Scholes Option Pricing Model [Line Items]
Risk-free interest rate		4.01%
Expected life	[1]	4 years 10 months 24 days				4 years 1 month 24 days

[1]On April 28, 2023, the Company amended the warrant agreements for the 231,828 derivative liability warrants outstanding. The amendment removed the clause to automatically convert warrants to shares on IPO date and all warrants were given an expiry date of April 27, 2027. This led to an increase in the expected life input in the Black-Scholes model as of December 31, 2023, compared to December 31, 2022, when the Company used the expected IPO date to calculate the expected life of the warrants.

Derivative Liabilities (Detai_4

Derivative Liabilities (Details) - Schedule of Derivative Liability Warrants Outstanding - Derivative Liability Warrants [Member]	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Schedule of Derivative Liability Warrants Outstanding [Line Items]
Outstanding \| shares	306,828
Weighted average exercise price \| $ / shares	$ 2.5
April 27, 2027 [Member]
Schedule of Derivative Liability Warrants Outstanding [Line Items]
Outstanding \| shares	75,840
Expiry date	Apr. 27, 2027	[1]
Weighted average exercise price \| $ / shares	$ 2.01
April 27, 2027 [Member]
Schedule of Derivative Liability Warrants Outstanding [Line Items]
Outstanding \| shares	63,037
Expiry date	Apr. 27, 2027	[1]
Weighted average exercise price \| $ / shares	$ 2.01
April 27, 2027 [Member]
Schedule of Derivative Liability Warrants Outstanding [Line Items]
Outstanding \| shares	80,388
Expiry date	Apr. 27, 2027	[1]
Weighted average exercise price \| $ / shares	$ 2.01
April 27, 2027 [Member]
Schedule of Derivative Liability Warrants Outstanding [Line Items]
Outstanding \| shares	12,563
Expiry date	Apr. 27, 2027	[1]
Weighted average exercise price \| $ / shares	$ 2.01
November 21, 2028 [Member]
Schedule of Derivative Liability Warrants Outstanding [Line Items]
Outstanding \| shares	75,000
Expiry date	Nov. 21, 2028	[1]
Weighted average exercise price \| $ / shares	$ 4

[1]On April 28, 2023, the Company amended the warrant agreements for the 231,828 derivative liability warrants outstanding. The amendment removed the clause to automatically convert warrants to shares on IPO date and all warrants were given an expiry date of April 27, 2027. This led to an increase in the expected life input in the Black-Scholes model as of December 31, 2023, compared to December 31, 2022, when the Company used the expected IPO date to calculate the expected life of the warrants.

Notes Payable (Details)

Notes Payable (Details) - USD ($)		9 Months Ended
Notes Payable (Details) - USD ($)	Jul. 31, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Notes Payable [Line Items]
Sell an aggregate amount		$ 914,442
Common stock issue (in Shares)		49,376,039		17,329,615
Transaction costs		$ (85,558)
Notes issued		622,239
Proceeds issuance of notes		6,993,059	1,463,586
Repaid notes payable		1,150,000
Notes payable balance
Securities Purchase Agreement [Member]
Notes Payable [Line Items]
Sell an aggregate amount	$ 1,150,000
Original issue discount	$ 150,000
Common stock issue (in Shares)	1,299,999
Original issue discount	$ 1,000,000
Non-interest bearing per annum	14%
Fair value of notes	$ 622,239
Transaction costs	137,500
Notes issued	85,558
Proceeds issuance of notes	$ 51,942
Repaid notes payable		$ 1,150,000

Notes Payable (Details) - Sched

Notes Payable (Details) - Schedule of Notes Payable	9 Months Ended
Notes Payable (Details) - Schedule of Notes Payable	Sep. 30, 2024 USD ($)
Notes Payable [Abstract]
Outstanding, December 31, 2023
Fair value of Notes issued	622,239
Transaction costs	(85,558)
Interest accretion	613,319
Repayment	(1,150,000)
Outstanding, September 30, 2024

Equity (Details)

Equity (Details) - USD ($)																		1 Months Ended	2 Months Ended	3 Months Ended	9 Months Ended		12 Months Ended
Equity (Details) - USD ($)	Nov. 01, 2024	Sep. 24, 2024	Sep. 13, 2024	Aug. 02, 2024	Aug. 01, 2024	May 03, 2024	Apr. 30, 2024	Mar. 06, 2024	Sep. 13, 2023	Aug. 25, 2023	Jul. 01, 2023	Jun. 30, 2023	May 15, 2023	Apr. 14, 2023	Mar. 02, 2023	Feb. 01, 2023	Jan. 06, 2023	Jan. 31, 2024	Jun. 30, 2023	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Jun. 30, 2024	Apr. 28, 2023	Jul. 15, 2022
Equity [Line Items]
Common stock, shares authorized																				300,000,000	300,000,000		300,000,000
Par value (in Dollars per share)																				$ 0.0001	$ 0.0001		$ 0.0001
Common stock, shares issued																				49,376,039	49,376,039		17,329,615
Common stock, shares outstanding																				49,376,039	49,376,039		17,329,615
Acquisition of common shares		8,900,000		1,299,999
Recognized in equity (in Dollars)																					$ 1,610,778
Recognized share issued value (in Dollars)		$ 2,857		$ 130					$ 8	$ 5										$ 7,045,000	$ 7,045,000
Common stock additional paid in capital (in Dollars)		$ 7,042,143		325,689		$ 1,117,710	$ 492,850		$ 249,996	$ 139,995				$ 293,579
Fully vested shares	612,500				612,500	612,500															2,450,000
Number of stock issued																					950,000
Transaction costs (in Dollars)				51,942
Pre funded warrants		19,671,425
Pre funded warrants percentage		4.99%
issuance warrants percentage		9.99%
Exercisable price (in Dollars per share)		$ 0.28																									$ 2.01
Issuance costs (in Dollars)		$ 955,000
Stock options, shares																	62,500
Exercise price per share (in Dollars per share)								$ 1			$ 5	$ 5				$ 5	$ 0.6		$ 5
Common stock, value (in Dollars)																	$ 37,500			$ 4,938	$ 4,938		$ 1,733
Stock options value (in Dollars)								$ 52,845								$ 10,767		$ 16,178	$ 584,787
Number of common stock purchase warrants															250,000
Warrants issued																											231,828
Floor price (in Dollars per share)																					$ 0.056
Expiration, term			180 days
Warrants outstanding																										231,828
Warrants outstanding term																				3 years 9 months 21 days	3 years 9 months 21 days		2 years 9 months 21 days
Granted stock options																					92,500		234,000
Contractual life								10 years			10 years					10 years		10 years	10 years
Exercise price (in Dollars per share)																		$ 5
Percentage of option vesting for remaining period												75%							75%
Reissued options												80,000
Stock options value (in Dollars)											$ 3,940											$ 37,500
Options vest, percentage											25%
Remaining options vest, percentage											75%
Weighted average life of stock options outstanding																					7 years 10 days		7 years 10 months 2 days
Equity interest [Member]
Equity [Line Items]
Equity interest															50%
Pre-Funded Warrants [Member]
Equity [Line Items]
Acquisition of common shares		51,142,850
Exercisable price (in Dollars per share)		$ 0.0001
Warrants issued		28,571,425
Warrants [Member]
Equity [Line Items]
Common stock, shares issued			99,998						99,998
Recognized share issued value (in Dollars)															$ 750,000
Number of stock issued															250,000
Exercisable price (in Dollars per share)			$ 3												$ 3
Expiration, term			180 days
Series A Warrant [Member]
Equity [Line Items]
Number of shares		1
Placement Agent Warrants [Member]
Equity [Line Items]
Exercisable price (in Dollars per share)		$ 0.336
Warrants issued		1,428,571
Equity Option [Member]
Equity [Line Items]
Number of stock issued																					1,225,000
Number of shares allocated																							1,734,188	1,734,188
Granted stock options								80,000			1,500					10,000		12,500	222,500
Share based compensation expense (in Dollars)																					$ 57,521		$ 346,549
Share-Based Payment Arrangement, Tranche One [Member]
Equity [Line Items]
Fully vested shares						2,450,000
Black-Scholes Option Pricing Model [Member]
Equity [Line Items]
Vesting percentage																		25%	25%
Percentage of option vesting for remaining period																75%		75%
Independent Directors [Member]
Equity [Line Items]
Vesting percentage								25%								25%
Percentage of option vesting for remaining period								75%
Common Stock [Member]
Equity [Line Items]
Common stock, shares issued			83,332						83,882	46,666			10,000	97,681	250,000		62,500
Common stock, shares outstanding												9,988,836							9,988,836	49,376,039	49,376,039	10,118,834	17,329,615	9,568,475	18,892,115
Acquisition of common shares							950,000													612,500	2,175,000
Recognized in equity (in Dollars)						$ 1,117,833	$ 492,945													$ 62	$ 218
Recognized share issued value (in Dollars)		$ 7,045,000		$ 325,819		$ 123	$ 95						$ 1	$ 10	$ 25					$ 2,857	$ 2,857
Common stock additional paid in capital (in Dollars)													$ 29,999
Fully vested shares																					918,245
Number of stock issued																				28,571,425	28,571,425
Stock options value (in Dollars)																	$ 6
Number of shares																				1,299,999	1,299,999
Stock options value (in Dollars)																						$ 6
Additional Paid-in Capital [Member]
Equity [Line Items]
Recognized in equity (in Dollars)																				$ (62)	$ 1,610,560
Recognized share issued value (in Dollars)															$ 749,975					$ 7,042,143	$ 7,042,143
Stock options value (in Dollars)																	$ 37,494
Stock options value (in Dollars)																						$ 37,494
Preferred Stock [Member]
Equity [Line Items]
Preferred stock shares authorized																				75,000,000	75,000,000		75,000,000
Series A preferred stock, par value (in Dollars per share)																				$ 0.0001	$ 0.0001		$ 0.0001
Preferred stock, shares outstanding
Preferred stock, shares issued
Office and Administration [Member]
Equity [Line Items]
Share based compensation expense (in Dollars)																					$ 53,977		$ 3,543
Research and Development Expense [Member]
Equity [Line Items]
Share based compensation expense (in Dollars)																					$ 337,551		$ 8,998
Independent Director [Member]
Equity [Line Items]
Granted stock options																			80,000
Series A Preferred Stock [Member]
Equity [Line Items]
Exercisable price (in Dollars per share)																				$ 0.38	$ 0.38
Series A Preferred Stock [Member] \| Preferred Stock [Member]
Equity [Line Items]
Common stock, shares outstanding												1,861,799							1,861,799			1,861,799		1,861,799
Acquisition of common shares
Recognized in equity (in Dollars)
Recognized share issued value (in Dollars)
Number of stock issued
Number of shares
Stock options value (in Dollars)
Common Stock [Member]
Equity [Line Items]
Number of stock issued															250,000
Series A Warrants Outstanding [Member]
Equity [Line Items]
Floor price (in Dollars per share)																					$ 0.056
Warrants outstanding																				193,877,526	193,877,526
Series B Warrants Outstanding [Member]
Equity [Line Items]
Floor price (in Dollars per share)																					$ 0.056
Warrants outstanding																				188,194,300	188,194,300

Equity (Details) - Schedule of

Equity (Details) - Schedule of Equity Warrants - Warrant [Member]	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Schedule of Equity Warrants [Line Items]
Outstanding \| shares	58,921,419
Weighted average exercise price \| $ / shares	$ 0.39
August 28 2026 [Member]
Schedule of Equity Warrants [Line Items]
Outstanding \| shares	250,000
Expiry date	Aug. 28, 2026
Weighted average exercise price \| $ / shares	$ 3
March 12 2027 [Member]
Schedule of Equity Warrants [Line Items]
Outstanding \| shares	99,998
Expiry date	Mar. 12, 2027
Weighted average exercise price \| $ / shares	$ 3
October 30 2029
Schedule of Equity Warrants [Line Items]
Outstanding \| shares	28,571,425
Expiry date	Oct. 30, 2029
Weighted average exercise price \| $ / shares	$ 0.38
April 30, 2027 [Member]
Schedule of Equity Warrants [Line Items]
Outstanding \| shares	28,571,425
Expiry date	Apr. 30, 2027
Weighted average exercise price \| $ / shares	$ 0.38
March 24, 2028 [Member]
Schedule of Equity Warrants [Line Items]
Outstanding \| shares	1,428,571
Expiry date	Mar. 24, 2028
Weighted average exercise price \| $ / shares	$ 0.34

Equity (Details) - Schedule o_2

Equity (Details) - Schedule of Black-Scholes Option Pricing Model	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Schedule of Black-Scholes Option Pricing Model [Line Items]
Expected life	10 years	10 years
Expected dividend rate	0%	0%
Expected volatility	100%	100%
Forfeiture rate	0%	0%
Minimum [Member]
Schedule of Black-Scholes Option Pricing Model [Line Items]
Risk-free interest rate	3.95%	3.39%
Maximum [Member]
Schedule of Black-Scholes Option Pricing Model [Line Items]
Risk-free interest rate	4.19%	3.86%

Equity (Details) - Schedule o_3

Equity (Details) - Schedule of Stock Options - $ / shares	9 Months Ended	12 Months Ended
Equity (Details) - Schedule of Stock Options - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Schedule of Stock Options [Abstract]
Outstanding, Number of stock options beginning	1,523,084	1,366,167
Outstanding, Weighted average exercise price beginning	$ 1.71	$ 1.08
Granted, Number of stock options	92,500	234,000
Granted, Weighted average exercise price	$ 1.54	$ 5
Forfeited, Number of stock options	(394,990)	(14,583)
Forfeited, Weighted average exercise price	$ 2.2	$ 0.6
Exercised, Number of stock options		(62,500)
Exercised, Weighted average exercise price		$ 0.6
Outstanding, Number of stock options ending	1,220,594	1,523,084
Outstanding, Weighted average exercise price ending	$ 1.52	$ 1.71

Equity (Details) - Schedule o_4

Equity (Details) - Schedule of Right To Purchase One Common Stock Option Held - Common Stock [Member]	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	1,220,594
Vested	918,245
Stock Option One [Member]
Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	816,677
Vested	763,203
Expiry date	Feb. 08, 2031
Weighted average exercise price ($) (in Dollars per share) \| $ / shares	$ 0.6
Stock Option Two [Member]
Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	35,417
Vested	35,417
Expiry date	Feb. 27, 2031
Weighted average exercise price ($) (in Dollars per share) \| $ / shares	$ 0.6
Stock Option Three [Member]
Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	5,000
Vested	3,021
Expiry date	Apr. 25, 2032
Weighted average exercise price ($) (in Dollars per share) \| $ / shares	$ 0.6
Stock Option Four [Member]
Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	16,000
Vested	9,000
Expiry date	Jun. 01, 2032
Weighted average exercise price ($) (in Dollars per share) \| $ / shares	$ 1.34
Stock Option Five [Member]
Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	16,000
Vested	8,000
Expiry date	Sep. 30, 2032
Weighted average exercise price ($) (in Dollars per share) \| $ / shares	$ 1.34
Stock Option Six [Member]
Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	80,000
Vested	40,000
Expiry date	Sep. 30, 2032
Weighted average exercise price ($) (in Dollars per share) \| $ / shares	$ 5
Stock Option Seven [Member]
Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	10,000
Vested	4,792
Expiry date	Oct. 15, 2032
Weighted average exercise price ($) (in Dollars per share) \| $ / shares	$ 1.34
Stock Option Eight [Member]
Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	5,000
Vested	2,292
Expiry date	Nov. 01, 2032
Weighted average exercise price ($) (in Dollars per share) \| $ / shares	$ 5
Stock Option Nine [Member]
Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	10,000
Vested	3,958
Expiry date	Mar. 02, 2033
Weighted average exercise price ($) (in Dollars per share) \| $ / shares	$ 5
Stock Option Thirteen [Member]
Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	50,000
Vested	16,666
Expiry date	Apr. 16, 2033
Weighted average exercise price ($) (in Dollars per share) \| $ / shares	$ 5
Stock Option Fourteen [Member]
Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	80,000
Vested	28,333
Expiry date	May 01, 2033
Weighted average exercise price ($) (in Dollars per share) \| $ / shares	$ 5
Stock Option Fifteen [Member]
Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	10,000
Vested	3,125
Expiry date	Jun. 27, 2033
Weighted average exercise price ($) (in Dollars per share) \| $ / shares	$ 5
Stock Option Seventeen [Member]
Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	1,500
Vested	438
Expiry date	Jul. 01, 2033
Weighted average exercise price ($) (in Dollars per share) \| $ / shares	$ 5
Stock Option Nineteen [Member]
Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	5,000
Vested
Expiry date	Feb. 12, 2034
Weighted average exercise price ($) (in Dollars per share) \| $ / shares	$ 5
Stock Option Twenty [Member]
Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	80,000
Vested
Expiry date	Mar. 05, 2034
Weighted average exercise price ($) (in Dollars per share) \| $ / shares	$ 1

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)		9 Months Ended		12 Months Ended
Related Party Transactions (Details) - USD ($)	Mar. 01, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Related Party Transactions [Line Items]
Percentage of authority control		10%
Vesting percentage	25%
Related parties were forfeited (in Shares)		354,990
Unsecured amount		$ 22,217		$ 22,455
Line of credit		$ 200,000
Percentage of outstanding principal		20%
Accrued line of credit		$ 6,833
GB Capital Ltd. [Member]
Related Party Transactions [Line Items]
Consulting fees		150,833	$ 63,750
Northstrive Companies Inc [Member]
Related Party Transactions [Line Items]
Consulting fees		111,100	90,000
Jordan Plews [Member]
Related Party Transactions [Line Items]
Consulting fees				4,272
Amount of salary paid		189,385	168,050
Employer taxes		21,051	18,050
Accrued salaries		60,539
Brenda Buechler [Member]
Related Party Transactions [Line Items]
Amount of salary paid		132,807	159,950
Employer taxes		14,297	17,446
Christoph Kraneiss [Member]
Related Party Transactions [Line Items]
Consulting fees				879
Amount of salary paid		122,818	148,131
Employer taxes		10,639	$ 13,131
Braeden Lichti [Member]
Related Party Transactions [Line Items]
Consulting fees		49,500		15,143
Share based compensation expense		22,217		22,455
Northstrive Companies Inc. [Member]
Related Party Transactions [Line Items]
Due to related party		$ 80,368		$ 34,378
Black-Scholes Option Pricing Model [Member]
Related Party Transactions [Line Items]
Percentage of option vesting	75%
Directors [Member]
Related Party Transactions [Line Items]
Stock options granted (in Shares)	80,000
Contractual life	10 years
Exercise price (in Dollars per share)	$ 1
Stock options value	$ 45,986

Related Party Transactions (D_2

Related Party Transactions (Details) - Schedule of Remuneration of Directors and Key Management Personnel - Related Party [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Related Party Transaction [Line Items]
Consulting fees	$ 101,100	$ 51,250	$ 261,933	$ 153,750
Salaries	67,353	159,874	445,009	476,126
Share-based compensation	30,764	124,994	(1,819)	247,348
Total	$ 199,217	$ 336,118	$ 705,123	$ 877,224

Related Party Transactions (D_3

Related Party Transactions (Details) - Schedule of Fair Value of the Options Granted to Each Individual and the Related Expense - USD ($)		9 Months Ended
		Sep. 30, 2024	Sep. 30, 2023
Related Party Transaction [Line Items]
Individual and related expense		$ (1,819)	$ 145,516
Fair value of stock options granted		1,049,898
Braeden Lichti, Chairman [Member]
Related Party Transaction [Line Items]
Individual and related expense	[1]	1,894	5,398
Fair value of stock options granted	[1]	50,995
Graydon Bensler, CEO, CFO and Director [Member]
Related Party Transaction [Line Items]
Individual and related expense		1,897	5,398
Fair value of stock options granted		50,995
Jordan Plews, Director and CEO of Skincare and BioSciences [Member]
Related Party Transaction [Line Items]
Individual and related expense		1,897	5,398
Fair value of stock options granted		50,995
Tim Sayed, Former Chief Medical Officer and Former Director [Member]
Related Party Transaction [Line Items]
Individual and related expense	[1]	(4,291)	5,398
Fair value of stock options granted	[1]	50,995
Jeffrey Parry, Director [Member]
Related Party Transaction [Line Items]
Individual and related expense		18,564	21,177
Fair value of stock options granted		107,669
Crystal Muilenburg, Former Director [Member]
Related Party Transaction [Line Items]
Individual and related expense	[1]	(41,668)	46,725
Fair value of stock options granted	[1]	210,245
Julie Daley, Director [Member]
Related Party Transaction [Line Items]
Individual and related expense		69,111	56,022
Fair value of stock options granted		210,245
George Kovalyov, Director [Member]
Related Party Transaction [Line Items]
Individual and related expense		18,144
Fair value of stock options granted		52,845
Brenda Buechler, Former Chief Marketing Officer [Member]
Related Party Transaction [Line Items]
Individual and related expense	[1]	(36,918)
Fair value of stock options granted	[1]	143,671
Christoph Kraneiss, Former Chief Commercial Officer [Member]
Related Party Transaction [Line Items]
Individual and related expense	[1]	(30,449)
Fair value of stock options granted	[1]	$ 121,243

[1]354,990 options of related parties were forfeited in the nine months ended September 30, 2024.

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Commitments and Contingencies [Abstract]
Commitments amount

Concentrations (Details)

Concentrations (Details) - USD ($)	9 Months Ended
Concentrations (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Concentrations [Line Items]
Customer revenue (in Dollars)	$ 139,149
Customer Concentration Risk [Member] \| Largest Customer [Member] \| Revenue Benchmark [Member]
Concentrations [Line Items]
Revenue percentage		14%
Supplier Concentration Risk [Member] \| Revenue Benchmark [Member] \| Three Suppliers [Member]
Concentrations [Line Items]
Revenue percentage	78%	66%

Concentrations (Details) - Sche

Concentrations (Details) - Schedule of Suppliers Percentage of Cost - Supplier Concentration Risk [Member] - Revenue Benchmark [Member]	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Supplier 1 [Member]
Schedule of Suppliers Percentage of Cost [Line Items]
Total	37%	26%
Supplier 2 [Member]
Schedule of Suppliers Percentage of Cost [Line Items]
Total	29%	23%
Supplier 3 [Member]
Schedule of Suppliers Percentage of Cost [Line Items]
Total	12%	17%
Total Suppliers [Member]
Schedule of Suppliers Percentage of Cost [Line Items]
Total	78%	66%

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - $ / shares	Nov. 01, 2024	Oct. 03, 2024
Subsequent Events [Line Items]
Common stock issued		155,890,910
Common stock outstanding		155,890,910
Common stock with a par value (in Dollars per share)		$ 467,672,730
IPR&D [Member]
Subsequent Events [Line Items]
Acquisition of shares	612,500
Series B Preferred Stock [Member]
Subsequent Events [Line Items]
Newly issued Shares of preferred Stock		32,303,390